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  Abstract 
Objective: To retrospectively evaluate intravenous antifungal medications in paediatric 
patients in a public hospital for children. 
Method: Data relevant to the antifungal prescription were collected for all the patients 
<18 years of age who had been prescribed IV antifungal therapy. All paediatric patients 
prescribed intravenous antifungal treatment for one year (July 2006 to 30th June 2007) at 
PMH were evaluated retrospectively. The data collected were evaluated against the 
Australian Therapeutic Guidelines:  Antibiotic Version 13 and hospital in house 
guidelines for IV antifungal therapy from the microbiology department at the hospital.   
Results: There were 59 patients included in the study and the most frequently diagnosed 
disease was leukemia. Of the total 59 patients, liposomal amphotericin B (L-AmB) was 
prescribed for 47 patients, conventional amphotericin B (C-AmB) for four patients, 
caspofungin for two patients and voriconazole for one patient. Five patients received 
combination antifungals. The dose of C-AmB was 1 mg/kg/day. Voriconazole dose of 5 
mg/kg/day was given for a period of four days for one patient. Nine patients included in 
this study were neonates and they were prescribed L-AmB, C-AmB and a combination of 
Voriconazole and L-AmB. 34 patients out of 47 were prescribed 3mg/kg/day of L-AmB 
and the highest L-AmB dose prescribed was 5 mg/kg/day and the lowest dose was 1 
mg/kg/day. The median number of days for L-AmB treatment was found to be 11 days 
and the maximum was 51 days. Additionally 6% of patients who received L-AmB had 
oral fluconazole recommended r five days after cessation of L-AmB.  It was found that 
27% of patients had a low potassium level and a significantly higher proportion of 
patients had abnormal alanine aminotransferase and 11(18.6%) of the 59 patients had 
abnormal serum creatinine levels. It was found that the mean temperature decreased to 
37.0˚C   from a 38.3˚C   from commencement to the cessation of the IV antifungal 
treatment. The longest duration of antifungal treatment in this study period was L-AmB 
prescribed for a period of 102 days.  
 
 iv 
The estimated treatment cost for the longest treatment in this study was found to be AUD 
34,222 if prepared in the pharmacy (CIVAS) and AUD 43,784 if prepared in the ward 
setting. Estimated total treatment cost for a four year old patient with a bodyweight of 21 
kg on L-AmB for a period of 21 days was found to be AUD 7,803 when prepared in 
Pharmacy (CIVAS) and AUD 12,029 for Ward reconstitution. 
Conclusion: The data from this study indicated a satisfactory quality of IV antifungal 
treatment; however the remaining requirements for appropriate use required additional 
education. This study found that L-AmB was the antifungal agent of choice. Considerable 
savings could be made for pharmacy reconstituted IV antifungals by CIVAS over a ward 
setting where wastage occurs from unused antibiotic vials. At present the understanding 
of newer antifungal agents in children is limited. In future children should be included in 
the studies of new antifungal drugs and combination therapy and stratify the results by 
age, given the potential differences in pharmacokinetics, pharmacodynamics, efficacy 
and safety and cost.  
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Abbreviations 
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1 Introduction 
The incidence and severity of invasive fungal infections (IFIs) in immunocompromised 
patients has dramatically increased worldwide during the last two decades.1  Mortality 
and morbidity in patients with life-threatening conditions have reduced due to the 
advances in supportive medical care, cancer therapy, stem cell and solid organ 
transplantation. However these advances have also contributed to an increased population 
of patients vulnerable to IFIs.2  
The incidence of  invasive fungal infection (IFIs) in USA has increased 307% from 5231 
cases in 1979 to 16,042 cases in 2000.3 The fourth commonest nosocomical bloodstream 
pathogen with the highest crude mortality (40%) in the USA is the Candida spp.4 New 
and emerging fungal pathogens such as Zygomycetes, Fusarium spp. or Scedosporium 
spp. have become increasingly important in addition to Candida spp. and Aspergilus spp. 
Empirical antifungal therapy has become the standard of care in neutropenic patients in 
whom fever persists despite treatment with broad spectrum antibiotics.5 Despite the 
development of novel antifungal drugs and advances in medical interventions the crude 
and attributable mortality of IFIs has remained largely unchanged over the past 20 
years.6,7 
The new age of opportunistic fungal pathogens extends to paediatric patients with 
immunodeficiencies especially those with disorders of neutrophil function.8 
Unfortunately there are only a few paediatric focused studies on the epidemiology and 
treatment of IFIs in children although knowledge of newer antifungals has been expanded 
by recent studies. Many recommendations for the use of antifungals in children are 
derived from experience in adult patients.2 
Three treatment strategies are available, dependent on whether an IFI is possible, 
probable or proven: prophylactic, empiric and specific. Two new triazoles and three new 
echinocandins have been approved by FDA for use in the last 6 years increasing the 
options for prophylaxis and treatment of IFIs. Amphotericin B deoxycholate (C-AmB) 
remains the‛gold standard’ for the management of many invasive fungal infections in 
adults and children, as well as the comparative agent for all newer antifungal agents.9 At 
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the beginning of the 1990s, the pace of drug development accelerated with the 
introduction of triazoles. Amphotericin B (C-AmB) was incorporated in three lipid 
formulations, whilst itraconazole and first generation triazoles changed the epidemiology 
of Candida infections and offered new treatment options.10 In many cases these 
antifungals have proven to be less toxic and more effective than C-AmB.11 The choice of 
the most appropriate drug should be guided by efficacy, safety and economic criteria.12 
Voriconazole is a second  generation triazole antifungal agent approved by FDA in May 
2002 available as both IV and oral formulations.13 It has added a new and improved 
therapeutic option for primary therapy of invasive aspergillosis and demonstrated 
survival benefit and superior efficacy with C-AmB followed by other antifungal 
therapy.14 
Antifungal therapy is influenced by a multiplicity of factors including patient risk profile, 
based on the underlying condition  versus relapsing episodes of fever, whether antifungal 
prophylaxis has been used, clinical presentation, documentation of bacterial infection and 
results of non-invasive diagnostic tools.12 
1.1 Fungal infections 
The fungal infections which are increasing in frequency are responsible for most fatal 
infections in patients with acute leukemia and other cancers.15 Factors leading to 
increased incidence of fungal infections in cancer patients include more irradiation 
leading to long term granulocytopenia (>14 days), more aggressive cancer chemotherapy 
and complicated surgical procedures, damage of mucosal barriers, invasive treatments 
and procedures, use of potent broad spectrum antibiotics, prolonged serious illness and 
pharmacological doses of corticosteroids.15,16 
The incidence of fungal infections in cancer patients is 15-25% for patients with 
leukemia or those undergoing bone marrow transplant, 10% for those with lymphoma, 
and 5% for those with solid tumors.Autopsy studies have shown that these infections are 
primarily due to either Candida or Aspergillus species.17,18 Knowledge and management 
of patients with Systemic fungal infection (SFI) has improved concurrently with the 
emergence of new therapeutic compounds and with an improved understanding of the 
nature of the disease, although there remains problems in diagnosis and prevention.19 
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In a myeloid leukemia trial,20 two-thirds of the 13.8% of treatment related mortality was 
due to fungal infections leading to 2.3% mortality rate. Candidaemia or bacteraemia 
occurred in two of the eight fatal SFI cases and aspergillus pneumonia occurred in six. 
During the second half of the study the treatment related death rate was halved, possibly 
related to increased clinical awareness, improved therapy of leukostasis, inpatient 
hospital management and the use of prophylactic azoles. 
 The Munster study21 on 433 children with malignancy, identified AML as a high risk 
factor. The SFI rate in acute lymphoblastic leukaemia was 8.5% compared to 47% in 
AML. SFI was developed in 15% of patients with haematological malignancies compared 
to 0.9% of children with other malignancies. Finally for patients with long-term 
indwelling intravenous catheters the SFI rate was 39% compared with 8.5% in those 
without them. This risk factor does emphasize the great importance of strict aseptic 
management of such lines although is confounded by its greater use in higher risk 
patients. 
Candida spp. are the most predominant causes of invasive fungal infections, pathogens.10 
In the USA, the annual incidence of Candida associated blood stream infections ranged 
from 6 to 23 per 100,000 persons22 and in European countries from 2.5 to 11 per 100,000 
persons.23 The incidence of nosocomical blood stream infections due to Candida spp. 
from 1981 to 2005 at the National Taiwan University Hospital is shown in Figure 1.23, 24 
Despite advances in medical care, crude mortality rates remain, high ranging from 30% 
to 50%.23,24 Candida parapsilosis occurs with high frequency in premature neonates,  
pediatric patients and in patients with vascular catheters23,25 and Candida tropicalis in 
patients with hematological malignancy.23,26 Nearly 20% of the isolates of  Candida. 
parapsilosis were resistant in vitro to amphotericin B, which may have an important 
implication in selection of an antifungal agent for this organism, which is commonly 
encountered in paediatric patients. In addition, persistent fungaemia in paediatric patients 
is associated with amphotericin B resistance.27 Recently in a neonatal intensive care unit, 
Candida tropicalis had been observed as a cause of fungaemia.28 Reports have shown that 
Candida crusei possesses decreased susceptibility to amphotericin B and intrinsic 
resistance to fluconazole has also been reported.29, 30 Although cross resistance was noted 
within the azoles in some Candida glabrata, new triazoles such as voriconazole, 
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posaconazole and the echinocandins are active against Candida tropicalis and Candida 
glabrata.29,30,11 
Figure 1  Incidence of nosocomical bloodstream infections (BTI) due to Candida spp. among 
patients treated at National Taiwan University Hospital, Taiwan, 1981-200523,24  
 
 
Aspergillus species, chiefly Aspergillus fumigatus and Aspergillus flavus occurs 
predominantly in highly immunocompromised patients mainly in patients with 
haematological malignancies and/or those receiving haematopoietic stem cell 
transplantation. Environmental exposure, prolonged granulocytopenia and use of 
corticosteroids are the major risk factors. During the years 1999-2000 there had been an 
increase in the number of invasive aspergillus infections among  patients with 
haematological malignancies while there had been a relative stability in yeast and non-
aspergillus ‘mould’ infections.31 In a large Italian multicentre study of invasive mould 
infections among patients with haematological malignancies, 65% of 14 cases of invasive 
aspergillosis and 69% of 310 cases of invasive aspergillosis were diagnosed in patients 
with AML. A significantly lower proportion of patients with haematological 
malignancies other than AML  were affected by invasive aspergillosis, however fatality 
rates among other patient subgroups with haematological malignancy and invasive 
aspergillosis was not lower than in patients with AML.31 Between 1998 and 2003, in a 
French survey of 88 cases of invasive aspergillosis diagnosed, patients with 
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haematological malignancies were the majority of the cases documented.32 The majority 
of Aspergillus species were susceptible to amphotericin B, extended spectrum triazoles 
and the echinocandins, although Aspergillus terreus was considered particularly resistant 
to amphotericin B.29,32 Reports from recent studies33,34 suggested that the new triazoles, 
voriconazole and posaconazole were more effective than fluconazole for preventing 
invasive aspergillosis in patients receiving haematopoietic stem cell transplantation. 
1.2 Amphotericin B 
A macrocyclic polyene, Amphotericin B deoxycholate (C-AmB), has been available for 
more than 40 years characterized in-vitro by a broad antifungal activity covering most of 
the fungal pathogens involved in human disease in clinical practice.35 It has been the drug 
of choice for IFIs over other antifungal agents and it is licensed for the greatest number of 
indications.  
During the treatment of most IFIs, resistance to amphotercin B remains uncommon. 
Intrinsic resistance to amphotericin B is rare in Candida species, however the results of a 
study showed a significant higher mortality in immunocompromised patients with 
candidaemia due to isolates with amphoteriicn B elevated mean inhibitory concentrations 
MIC > 0.8 mg/liter.36 Resistance with C. lustiane strains and likely resistance with C. 
gulliermondi have been reported.37 Elevated MIC values occur  in other non-albican 
Candida species such as C. glabrata and C. krusei, but are usually still considered 
susceptible.38 Trichosporon species are resistant to amphotericin B, but resistance of 
Cryptococcus neoformans to amphotericin B is rare.39 Reports of clinical failure and in-
vitro resistance with amphotericin B  among the filamentous fungi  can be seen in 
Pseudoallescheria boydii, Fusarium species, Scedosporium species, Aspergillus terreus 
and occasionally Aspergillus flavus.40 
The conventional form of amphotericin B is well known for its acute and chronic 
toxicities  like nephrotoxicity, hypokaleamia, elevated serum creatinine levels, fever, 
chills, vomiting and has consequently limited its potential use for systemic therapy.41 The 
aim to reduce amphotericin toxicities and to improve its effectiveness during the last ten 
years involved several strategies including chemical modification of amphotericin B and 
changes in delivery systems. In this respect, three lipid formulations of amphotericin B 
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are currently available commercially as shown in Table 1. These lipid formulations differ 
in several aspects, in their lipid composition, shape, physiochemical properties42 and 
pharmacokinetic and pharmacodynamic properties as demonstrated by several preclinical 
and clinical trials that reported then to be less toxic than amphotericin B (Fungizone).43 
Table 1  Lipid formulations of amphotericin B : general characteristics:42 PK/PD properties42, 
44,45  
Generic Trade Dose Cmax Vd AUC Plasma
Name Name (mg/kg) (mg/l) (l/kg) (mg h/l) Half
Life(h)
AmBD Fungizone 1958 - 0.6 1.1 5.1 17.1 27-39
ABLC Abelect 1995 1:03 5 1.7 131 9.5 16
ABCD Amphocil 1996 1:01 5 3.1 4.3 43 28
L-AmB Ambisome 1997 1:09 5 83 0.11 555 8.6
FDA 
approval
Amphotericin 
B: lipid ratio
 
Lipid formulations of amphotericin B have been licensed in many countries for the 
following indications.11 
ABCD (Amphocil):  for patients with aspergillosis in whom previous C-AmB therapy 
had failed and for invasive aspergillosis in patients in whom renal impairment or 
unacceptable toxicity precludes the use of C-AmB in effective doses. Approved dosage is 
3-4 mg/kg per day. 
ABLC (Abelect): for treatment of IFIs (Candidiasis included) in patients who are 
refractory or intolerant to C-AmB. Approved dosage is 5 mg/kg per day. 
L-AmB (Ambisome): for treatment of systemic aspergillus and candida infections and of 
cryptococcal meningitis in patients positive for HIV infection, in patients in whom renal 
impairment or unacceptable toxicity precludes the use of C-AmB; for empirical therapy 
of presumed fungal infection in febrile neutropenic patients; treatment of visceral 
leishmaniais. Dosage approved is 6 mg/kg per day for cryptococcal meningitis in patients 
with HIV infection, 3 mg/kg per day for empirical therapy in neutropenic patients and 3-5 
mg/kg per day for systemic fungal infections. 
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Amphotericin B has been shown to be more effective for the treatment of a broad 
spectrum of mycoses and been extensively studied in adult patients. However data in 
children are more limited.46 Due to the more rapid clearance in children, nephrotoxicity 
associated with amphotericin B is less severe in infants and children than in adults.2 The 
advantages are increased daily doses of the parent drug, reduced toxicity and better 
delivery to primary reticuloendothelial organs offered by the lipid formulations of 
amphotericin B.46,47 However, infusion related reactions and nephrotoxicity are variably 
reduced with L-AmB (ambisome) more than (ABLC) Abelect and more than (ABCD) 
Amphocil. There is little information from randomized trials other than for ambisome, 
and compared with Abelect and Amphocil, there is also much less need for 
premedication, including steroids for ambisome.19 A multicentre L-AmB (ambisome) 
study demonstrated that nephrotoxicity was significantly less prevalent (at 10%) for 1 
mg/kg ambisome and 12% for 3 mg/kg compared with a 24% incidence with C-Amb.48  
The results of a large review of patients who received ABLC suggested that children 
experienced less nephrotoxicity with the lipid formulation of amphotericin B. Elevation 
of serum creatinine level > 2.5 times baseline was experienced in  13% of patients aged > 
18 years of age compared to only 6% in patients aged < 18 years.49 The collaborative 
exchange of antifungal research assessed the safety and efficacy of amphotericin B lipid 
complex (ABLC) in 548 children who received at least four doses of ABLC. There were 
54.5% (139/255) of patients that showed a complete or partial response with 39.1% for 
invasive aspergillosis and 58.1% for invasive candidiasis. Overall transplant patients 
showed a lower response rate with a complete or partial response of 47% in patients with 
a documented fungal infection.2 A retrospective study of 46 children treated with ABLC 
reported a response rate of 89% against invasive candidiasis and 78% against invasive 
aspergillosis with an overall response rate of 83%.50 Concerning infusion related 
reactions and nephrotoxicity, L-AmB has proven less toxic than C-AmB (19% vs. 
34%).51 A randomized comparative  study52 on L-AmB 5 mg/day with C-AmB 1mg/kg 
per day in patients with invasive fungal infection and neutropenia suggested an improved 
response with L-AmB compared with C-AmB. The overall response rate was 52% for L-
AmB and 29% in C-AmB in patients with suspected or documented invasive 
aspergillosis. At completion of therapy a complete response of 64% was in seen in 
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patients receiving L-AmB and 17% in patients receiving C-AmB. A large randomized 
double blind trial53 compared L-AmB at two doses 3 and 5 mg/kg per day with ABLC 
(Abelect) at 5 mg/kg per day. Infusion related reactions occurred more than three times as 
often with ABLC compared to L-AmB and the incidence of hypoxia was higher in ABLC 
than seen with C-AmB and also a doubling of creatinine occurred in 42% of Abelect 
cases compared with 14.1% for L-AmB 3 mg/kg and 14.8% for L-AmB 5mg/kg.  
1.3 Echinocandins 
A new class of antifungals, the echinocandins has recently been developed. These are  
semi synthetic amphiphilic  lipopeptides, products of cyclopentamine, formed during the 
fermentation of fungi such as Aspergillus nidulans var.echinulatus or Zalerion 
arboricola.54 They exert selective antifungal activity by non-competitive  inhibition of 
1,3-β-glucan synthase  and thus interfering with the  cell wall biosynthesis.55,56,57 Thus 
glucans play a key role in cell division and cell growth and provide structural integrity to 
the fungal cell wall by forming a fibril of three helically-entwined linear 
polysachharides.58,59 Selective inhibition of glucan synthesis enzyme complies results in 
fungicidal activity against candida and fungistatic against aspergillus.57,60 
Echinocandins have variable activity against dematiaceous fungi and the endemic 
dimorphic pathogens in addition to activity against candida and aspergillus.56,57 Fusarium 
and other hyalohyphomycetes, Candida neoformans, Trichosporum spp, and other 
Zygomycetes are inactive against echinocandins.57 There are limited data on 
echinocandin resistance and this will need to be monitored with continued widespread 
use. Among Candida spp. and Aspergillus spp. primary resistance to echinocandins 
appears extremely uncommon.55 In laboratory derived mutants of sachromyces cerevisae, 
resistance has been shown to occur via mutations in the genes that encode for the β-
glucan synthase complex.57 Notable fluconazole resistant strains of Candida spp are 
active against echinocandins.61,62 
 
The echinocandins currently in use are listed  below.10 
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Caspofungin: approved in 2001 by the FDA for the treatment of patients with invasive 
aspergillosis who are refractory to other antifungal treatments. It was also approved   
subsequently for treatment of peritonitis, intra abdominal abscesses, oesophageal 
candidiasis, and pleural space infections caused by Candida spp., and for the treatment of 
fever in patients with neutropenia. 
Micafungin: first available in 2005 when it was approved for the treatment of 
oesophageal candidiasis and prophylaxis in patients undergoing stem cell transplantation. 
Anidulafungin: approved in 2006 for the use in the treatment of oesophageal 
candidaemia, peritonitis, oesophageal candidiasia and intra-abdominal abscesses due to 
Candida spp. 
All the above agents are water soluble and are available only for IV use.63  Echinocandins  
have  dose-dependent linear pharmacokinetics  and are highly protein bound.64 Although 
the concentrations in cerebrospinal fluid are low, the echinocandins are broadly 
distributed to all major organs.65 Metabolism occurs by a cytochrome p-450 independent 
mechanism in the liver and excretion of inactive metabolites is in the faeces and urine 
and excretion of the active form is less than 2%.65 The new agents broaden the choice of 
agents and the decision to use them has to be developed on clinical and 
pharmacoeconomic benefits. 
1.3.1 Caspofungin 
Caspofungin has potent in-vitro inhibitory activity against Aspergillus spp. and moderate 
activity against other moulds such as H. capsulatum, C. immitis and B. dermatidis and 
also against Pneumocytstis jiroveci and dematiaceous fungi. However, it has no activity 
against C. neoformans, Trichosporon spp., Fusarium spp., hyalohyphomycetes, 
zygomycetes and Sporothrix schenckii.62,66 Caspofungin has linear pharmacokinetics, is 
not metabolized by the CYP isoenzyme system56 and is primarily excreted by the liver.61 
Casopofungin is fungicidal and highly active in-vitro against most isolates of Candida 
Spp.67,68 There is no known maximum tolerated dose and no toxicity defined maximum 
length of therapy at present.56  
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In a randomized double-blind study69 comparing caspofungin and fluconazole in the 
treatment of  oesophageal candidiasis the clinical response rate was 81% for caspofungin 
vs. 85% for fluconazole and for activity against Candida glabrata the response rate  was 
93% vs. 67% for caspofungin and fluconazole respectively. Another randomized double 
blinded study70 compared caspofungin with amphotericin B for the treatment of 
oesophageal candidiasis and the clinical response rate for caspofungin was 74% (34 mg), 
91% (50 mg), 82% (70 mg) and the clinical response for amphotericin B was 63%. 
Two studies71,72 on the efficacy of caspofungin as salvage therapy for the treatment of 
aspergillosis showed a favorable response of 45% in one study71 and 44% partial or 
complete response in a second study.72 Only in cases of advanced insufficiency (Child-
Pugh scores 7-9) the dose should be adjusted, as caspofungin is not nephrotoxic.73 It has 
very few serious side effects and those reported include headache, fever, nausea, rash, 
elevation of hepatic enzyme levels and phlebitis at the site of infusion.10 No significant 
differences in adverse effects between caspofungin and fluconazole were found in a trial 
comparing caspofungin IV (50 mg daily) and fluconazole IV (200 mg daily) for 
esophageal candidiasis.69 Caspofungin has few significant drug interactions.74 It has been 
suggested that caspofungin with cyclosporine and tacrolimus caused elevated liver 
enzymes.75 However, this claim has been disputed by recent studies.76 
1.3.2 Micafungin  
Micafungin is an FDA approved antifungal agent that acts by inhibiting 1,3-§-D-glucan 
synthesis in the fungal cell wall.77 Micafungin has the same spectrum of antifungal 
activity as caspofungin. A study by Erica et al. demonstrated that micafungin exhibited 
potent in-vitro activity against C. glabrata and was effective against azole-resistant 
strains.78 It is metabolised in the liver with <1% of the intact drug unchanged in urine and  
is excreted in an inactive form in bile and faeces.79 A multicentre open label dose 
comparison study80 on micafungin in the treatment of deep-seated mycoses showed a 
clinical response rate of 60% in invasive pulmonary aspergillosis, 67% in chronic 
necrotising pulmonary aspergillosis, 55% in pulmonary aspergilloma and 100% in 
candidaemia. Another multicentre randomised double blind study,81 compared 
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micafungin with fluconazole for the treatment of oesophageal candidiasis and the 
endoscopic cure rate was 87.7% vs. 88% respectively.  
The results of a multicentre open label study82 on micafungin showed a clinical response 
rate of 83.2% for the treatment of invasive candidiasis. Micafungin has few side effects 
including nausea, vomiting, headache, phlebitis, diarrhoea and leukopenia. In addition 
symptoms like rash, facial swelling, haemolysis and vasodilatation have been reported.  
It interacts with nifedepine and sirolimus but it appears not  to interact with cyclosporine 
or tacrolimus.74 However, a recent study83 has suggested that cyclosporine levels should 
be monitored because micafungin is a mild inhibitor of cyclosporine metabolism. No 
other interactions have been described for micafungin. 
1.3.3 Anidulafungin 
Anidulafungin is the newest echinocandin antifungal drug approved for use in the USA 
and is most active in invasive fungal infections.84 It has a half life of 25 to 42 hours and 
no dose adjustment in renal failure or hepatic failure is required. The recommended daily 
dose is 200/100 loading dose/daily maintenance dose (in mg).85 A wide range of Candida 
spp., including species resistant to Amphotericin B (Candida lusitaniae), azoles (Candida 
crusei) and other echinocandins (C. parapsillosis) are sensitive to anidulafungin86,87 and 
also is highly active against Aspergillus spp.87  
An open label randomized study88 for the treatment of oesophageal candidiasis, 
anidulafungin showed an endoscopic success rate of 85%. Another open label dose 
ranging study89 on anidulafungin for the treatment of candideamia and invasive 
candidiasis showed a clinical response rate of 84% for 50 mg/day, 90% for 75 mg/day 
and 89% for 100 mg/day. Anidulafungin is a well tolerated drug with few side effects like 
hypotension, fever, constipation, nausea, vomiting, hypokalemia and elevated hepatic 
enzymes.90 If anidulafungin is administered rapidly histamine like reactions 
(hypotension, dyspnoea, flushing ) arise.90,63 
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1.4 Azoles 
 The azole antifungals are categorized into two broad classes, imidazoles and triazoles 
which differ in terms of their chemical structure. Among the imidazoles only ketoconzole 
has systemic activity and all triazoles have systemic activity. Triazoles include 
fluconazole, itraconazole, voriconazole, posaconazole and ravuconazole.91 The newer 
triazole antifungals (voriconazole, posaconazole and ravuconazole) have good activity 
against fluconazole resistant and itraconzole resistant Candida spp. and moulds.2 
They inhibit  fungal lanosterol 14-α-demethylase, which catalyses a late step in ergosterol 
biosynthesis leading to accumulation of methylated sterols in the fungal cell  membrane 
and depletion of ergosterol.92 Both groups have similar antifungal spectra and mechanism 
of action, but the triazoles are more slowly metabolized and have less effect on human 
sterol synthesis than the imidazoles. Intrinsic azole resistances such as C. glabrata and C. 
krusei have become more common with the increased use of fluconazole prophylaxis. In 
Candida spp., three mechanisms of azole resistance have been described: alteration of the 
target lanosterol 14-α-demethylase, reduced azole accumulation through active efflux and 
mutation in the ergosterol pathway allowing for the accumulation of less toxic sterols in 
the presence of azoles.93 The introduction of ketoconazole in the early 1980s allowed 
outpatient therapy for several endemic mycoses, notably histoplasmosis, blastomycosis, 
and coccidiodomycosis. At higher doses, ketoconazole could have significant toxicity but 
overall it was a safer drug than amphotericin B.94 In the 1990’s outpatient therapy for 
most endemic mycoses with a low incidence of toxicity had been enabled by triazoles.95 
These drugs were more easily administered and less toxic but cross resistance in Candida 
spp. was possible as the mechanism of actions of all traizoles is similar and such 
resistance was observed from paediatric HIV infected patients in isolates of C. albicans.96 
1.4.1 Fluconazole 
Fluconazole is fungistatic and the activity of fluconazole is concentration-independent 
and does not increase once the maximum fungistatic concentration is attained.97 It has a 
broad-spectrum antifungal activity and has proven efficacy against Cryptococcus 
neoformans and several Candida species and has been used with various levels of success 
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against blastomycosis, histoplasmosis, sporotrichosis, and coccidioidomycosis.98 
Fluconzole has been used to treat patients with cryptococcal meningitis, oesophageal 
candidiasis, oropharyngeal candidiasis and chronic disseminated candidiasis.99 It has 
better bioavailability (90%) in oral form than in intravenous form. Studies on fluconazole 
treatment in children outside the neonatal period are very few and the majority of the data 
is derived from studies performed in adults. In an open, prospective randomized study100 
fluconazole was found to be safe and effective in preventing invasive Candida infections 
in 50 children undergoing chemotherapy for cancer. There was a significant difference in 
the pharmacokinetics of fluconazle between adults and children. Brammer et al.101 
reviewed five separate fluconazole pharmacokinetic studies which included 101 infants 
and children ranging from 2 weeks to 16 years. The results of this study demonstrated 
that fluconazole clearance was more rapid in children than adults. Compared to adults (30 
hrs) the mean plasma half life of fluconazole was 20 hrs in children which suggested that 
the daily fluconazole dose needed to be approximately doubled for children over three 
months of age to 6-12 mg/kg/day. A recent study by Bodey et al.102 demonstrated that 
fluconazole is equally effective but less toxic than amphotericin B for prophylaxis in  
inpatients with leukemia. The use of fluconazole has fewer side effects and is limited to 
nausea, vomiting, anorexia, rash and a mild elevation of hepatic enzyme levels.103 
1.4.2 Itraconazole 
Itraconazole is widely used for a variety of serious fugal infections  including 
Aspergillus, Cryptococcus, Candida, Blastomyces, disseminated Penicillium mameffei  
and Histoplasma capsulatum.104 The mechanism of action is described as the impairment 
of the synthesis of ergosterol, an essential component of the fungal cell membrane.105  
The major metabolite, hydroxyl-itraconazole is assumed to be equivalent to that of 
itracoonazole in its antifungal activity.106 Because itraconazole is insoluble in aqueous 
media,107 it is orally administered and there is an urgent need for an intravenous 
formulation. The oral suspension is better absorbed on an empty stomach but 
administration of a capsular formulation with food  increases absorption.108 There is no 
need for dosage adjustment in the presence of renal function impairment because 
elimination of itraconazole is primarily hepatic.109 Itraconazole has less nephrotoxicity 
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than amphoteriicn B and compared to other conventional antifungal agents it has a 
broader spectrum of activity than fluconazole.110 It is well tolerated and a recent study 
reported that 10% of the subjects had nausea, vomiting and elevated transaminases 
occurred in 5% of the  subjects.111 Important interactions occur with itraconazole and 
concomitant use with cyclophosphamide should be discouraged and  prior or concurrent 
use of rifampin, caramazepine, phenytoin and phenobarbital should be avoided.112  
Compared to adults, children need twice daily dosing of itracoanzole. This is supported 
by a study of 26 children < 12 years  of age which reported that 5 mg/kg once daily 
dosing led to substantially lower serum levels in children (especially in children < 2 years 
of age).113 A recent randomized trial which compared fluconazole and itraconazole 
reported  similar overall clinical and mycological results and more importantly there were 
no serious side effects with either antifungal.114  
1.5 Extended spectrum triazoles 
The mechanism of action of second generation triazoles is by inhibition of  cytochrome 
P450(CYP450) dependent conversion of lanosterol to ergosterol which leads to an 
accumulation of toxic 14-α-methylsterols and a depletion of membrane associated 
ergosterol which results in inhibition of cell growth or cell death.2 Voriconazole which 
was approved for the treatment of fungal infections in 2002 and posaconazole which 
received US Food and Drug Administration (FDA) approval in September 2006 are the 
antifungal agents included in this class. Clinical trials of ravuconazole have not yet been 
completed.115 
1.5.1 Voriconazole 
 Voriconazole (V Fend;Pfizer Inc) is a newer extended spectrum triazole available in both 
oral and intravenous formulations.116,117 Voriconazole combines the increased 
bioavailability of fluconazole with the broad spectrum  antifungal activity of itraconazole. 
It has a very broad spectrum antifungal activity that includes Candida spp. C neoformans, 
Aspergillus spp. Trichosporon spp. Fusarium spp.  and other hyaline moulds, the endemic 
dimorphic fungi and dematiaceous fungi.118 It is fungistatic against Candida species and 
fungicidal against Aspergillus.119,120 Voriconazole encompasses anticandidal activity of 
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strains of C. albicans and C. glabrata and  C. Krusei and most, but not all with decreased 
susceptibility to fluconazole.30 Voriconazole  is also active against fungi that are resistant 
to amphotericin B, including A. terreus and P. boydii.121 The drug is not active against 
Zygomycetes and in patients receiving VCZ as prophylaxis, it has been reported that an 
increased number of breakthrough infections due to Zygomycetes are seen.122 
Voriconazole is well absorbed orally and has an excellent bioavailability of more than 
90%.123, 124  The IV preparation is solubilized in sulfobuytyl ether β-cylcodextrin sodium  
which is secreted by the kidneys, necessitating dose adaptation in cases of renal 
impairment125 and is administered twice a day at a dose of 3 to 6 mg/kg.126 Following 
oral administration steady state plasma levels range from 2 to 3 µg/ml  and 3 to 6 µg/ml   
after intravenous infusion.126 VCZ has excellent penetration into the central nervous 
system as well as other tissues and is 58% protein- bound.64  It is extensively metabolized 
in the liver via the cytochrome p- 450 enzyme family and less than 5% of a dose is 
excreted unchanged in urine.64, 123 Some of the population are poor metabolizers and 
some are extensive metabolizers due to ofpoint mutation in the gene encoding 
CYP2C19.127 About 20% of non-indian Asians and 5-7% of Caucasians have a 
deficiency in expressing this enzyme. As a result in these subjects voriconazole levels are 
as much as 4-fold greater than for homozygous subjects who metabolize the drug more 
extensively.128  
For primary therapy of invasive aspergillosis VCZ has added a new and improved 
therapeutic option and has become the drug of choice for this entity.129 In febrile 
neutropenic patients VCZ is often used as empirical treatment of fever, although it failed 
to gain approval for this indication by the US Food and Drug Administration (FDA).130 
With no apparent post antifungal effect VCZ exhibits concentration-independent 
fungistatic activity against Candida spp. and C. neoformans.131  An AUC: MIC ratio of 
20-25:1 was indicated by recent in-vivo studies of disseminated C. albicans infection for 
treatment success.132 In contrast, based on both time-kill studies VCZ appears to exert a 
dose-dependent fungicidal effect on Aspergillus 120,119 and clearance of fungal burden in 
target organs of animal models of invasive aspergillosis.133 
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In patients intolerant of, or with infections refractory to other antifungal agents,123 VCZ is 
approved for the primary treatment of invasive aspergillosis and for treatment of 
infections due to P. boydii and Fussarium Spp.134 For the primary treatment of 
aspergillosis VCZ is superior than amphotericin B deoxycholate134 and in an open label 
multicenter study129 of 116 patients with invasive aspergillosis a similar positive 
experience of VCZ was noted (at week 12 of treatment  a complete or partial response of 
53% versus 32% and a survival rate of 71% versus 58%). Likewise, approximately 40% 
of patients were successfully treated with VCZ as reported in a study of 422 patients with 
invasive aspergillosis.135  
Despite documented efficacy in the treatment of invasive aspergillosis and the prevention 
of breakthrough fungal infection in the same patient population, VCZ has not been 
approved anywhere for empirical treatment of febrile neutropenic patients.123, 134 VCZ is 
generally well tolerated and has few side effects, the most common of which are visual 
disturbances, mild elevation of transaminases and gastrointestinal symptoms.126 Other 
adverse effects include skin reactions which are less than 10% prevelant. Vomiting, 
diarrhea, abdominal pain and headache are also reported.64,134 Reversible disturbance of 
vision (photophobia), which occurs in 30% of patients is the most common side effect but 
is transient. A 50% reduction in VCZ dose was recommended for patients with mild to 
moderate hepatic dysfunction, whilst in patients with severe hepatic failure its use is 
contraindicated.10  
Discontinuation of the drug is rarely necessary as these side effects are reversible.122 
However, in a very small number of patients, severe reactions including Stevens-Johnson 
syndrome and toxic epidermal necrolysis have been reported.117,123 Five patients who 
developed facial erythema and chelitis have been described; one of these patients also 
developed lesions similar to those characteristic of discoid lupus erythematosus.136 With 
increased serum voriconazole levels the risk of developing hepatitis appears to 
increase.137  
1.5.2 Posaconazole 
Posaconazole (PCZ) is a hydroxylated analogue of itraconazole.10 It first became 
available in Europe in 2005 and was approved by the FDA in September 2006 for the 
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treatment of oropharyngeal candidiasis in HIV-positive patients.115 In addition, to these 
indications, The European Commission also approved PCZ as first line therapy for the 
treatment of invasive aspergillosis, fusariosis, chromoblastomycosis, mycetoma and 
coccidiodomycosis infections in patients who are intolerant of certain commonly used 
antifungal agents.115 As indicated by the findings of time-kill studies,138 PCZ exhibits 
fungicidal activity against specific species of yeasts.138,139  It has a fungicidal activity 
against Aspergillus spp and is also fungicidal against C. inconspicua, C. kefyr, C. Krusei , 
C.  lusitaniae and C. neoformans. But it is fungistatic against C albicans, C guillermondi, 
C glabrata, C parapsillosis and C tropicalis.138,140 The activity of PCZ against 
Zygomycetes is the major difference between PCZ and voriconazole and PCZ is the only 
antifungal agent besides AMB that is active against these fungi.10 PCZ has a prolonged 
post-antifungal effect against C albicans (20-30 hours) in-vivo.141 PCZ is available only 
in an oral formulation (400-800 mg/day in divided doses). Its oral availability is increased 
by administering  PCZ with a meal, in a suspension rather than a tablet and in divided 
doses and is excreted mainly in the faeces and a minor portion is metabolized in the liver 
through glucoronidation.142 Dependent on the number of daily doses, the bioavailability 
of PCZ is high but variable.143 An intravenous form of PCZ has been developed as a 
prodrug, but because of its poor aqueous solubility, it has not yet been evaluated  in 
human clinical trials.144,145 Drug interactions can occur due to the ability of PCZ to inhibit 
the CYP3A4 isoenzyme and its function as a substrate for P-glycoprotein.146 
Coadministration of tacrolimus with posaconazole has been found to significantly 
increase exposure to tacrolimus.147 In heart transplant recipients, a cyclosporine dose 
reduction of up to 28.6% was required due to the interaction between cyclosporine and 
PCZ.148 Coadministration of PCZ with cemetidine, phenytoin and rifabutin is not 
recommended as PCZ concentrations are lowered by the above drugs.142 
 A multicentred, randomized study33 for prophylaxis in neutropenia in 602 patients 
compared a dose of 200 mg three times a day of PCZ   for 12 weeks with fluconazole and 
itraconazole and the results suggested that PCZ was superior to fluconazole and 
itraconazole in prevention and improved overall survival. Another multicentred, 
randomized study34 on prophylaxis in graft-versus-host disease, demonstrated that PCZ 
was similar to fluconazole in all fungal infections and also superior to fluconazole in 
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preventing proven or probable aspergillosis (2.3% vs.7.0%). Overall success rate of 42% 
and a survival rate of 79% were shown in two salvage studies.149,150 
The acquisition cost of PCZ based on the 2007 average wholesale price in US dollars, 
was found to be (200 mg three times a day) $82.30 per day for prophylaxis of IFIs which 
is higher than the acquisition cost of fluconazole (400 mg four times a day; $28.80 per 
day) or itraconazole (200 mg twice a day; $39.80 per day).151 At the dosages commonly 
used in the treatment of fungal infections, the acquisition costs of PCZ 200 mg three 
times a day and voriconazole 200-300 mg twice a day were $82.30 per day and $74.30 to 
$111.50 per day respectively.151 Further pharmacoeconomic studies are needed to 
determine which agent is cost effective in these infections. 
1.5.3 Ravuconazole 
 Ravuconazole is an investigational triazole currently undergoing phase 2 clinical trials as 
an oral agent, but to optimize its therapeutic potential, development of an intravenous 
formulation was deemed necessary. An approach using a water-soluble prodrug was 
employed to develop an IV formulation, since the development of intravenous 
administration of ravuconazole was precluded by its poor solubility. 
Ravuconazole is a potent and broad spectrum antifungal agent with an excellent 
antifungal activity against fungal pathogens such as C. albicans, Cryptococcus 
neoformans. However several species of Mucorales, Fusarium and Scedosporium 
prolificans are not sensitive to ravuconazole. The drug is highly active against 
Aspergillus spp. and has inhibitory activity for other species of hyaline filamentous fungi, 
black moulds and zygomycetes as indicated by an in-vitro study.152 Evaluating the 
activity of ravuconazole against 923 clinical isolates of non-dermatophyte filamentous 
fungi ravuconazole was active against 56.2% of mucorales tested whereas only one third 
were sensitive to itraconazole and almost the whole collection of mucorales was not 
sensitive to voricoanzole. To date, no trials in humans using ravuconazole as treatment 
for IFIs have been published.10 
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1.6 Drug Audit 
According to World Health Organisation (WHO), drugs are frequently not used 
according to usually accepted criteria, nor used to their full potential.153 It has been 
recognised long ago that there is a need for drug audit to assess and improve the quality 
of medical care.154,155 When considering the appropriateness of drug usage, the 
prescribing habits of physicians are important as they regulate drug consumption. 
Differences in drug consumption patterns between similar populations in developed 
countries and the mortality and/or morbidity following inappropriate use of drug/s, 
adverse reactions and antimicrobial resistance have often been attributed to physicians. 
An important service of drug usage review/evaluation (DUR/DUE) is being provided by 
Pharmacists. The outcomes of these assessments often lead to improvements in cost-
effective prescribing and better utilisation of limited resources. As organisations are 
searching for methods of reducing their costs, this service is high in demand. A typical 
drug evaluation process generally involves a Pharmacist screening the literature and 
clinical data, developing and gaining agreement on practice guidelines in conjunction 
with other related departments and evaluating the collected data against it. The results of 
the review will be presented to the prescribers and methods to modify prescribing 
behaviour sought and then evaluated.156 
Using a Pharmacy based review, Folli et al157 identified physician ordering errors in two 
paediatric hospitals. They found that paediatric intensive care unit patients and paediatric 
patients younger than two years were particularly susceptible to errors, most of them 
were dosing errors.158 Of 10788 medication orders written for 1020 patients, 616 (5.7%) 
orders involved an error of drug ordering, transcribing, dispensing, administering or 
monitoring. There were five (0.8%) preventable adverse effects, 115 (18.6%) potential 
adverse drug events and 486 (80.5%) errors with relatively little potential for harm. A 
total of 320 (31%) patients experienced a medication error; 118 (12%) patients 
experienced two or more errors. The majority of errors occurred at the ordering stage 
(77.8%), followed by administering (12.8%) and transcribing (5.8%). The most frequent 
type of medication errors were dosing errors (28.4%).159 
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Adverse drug events and medication errors are serious problems in paediatrics. Compared 
with adults the relatively higher rates of potentially harmful errors in hospitalised 
children are more complex in paediatrics and underscore the need for safer systems in 
this setting. However, until recently the incidence of paediatric medication errors has 
received relatively little scrutiny compared with adults and even less has been done to 
assess their preventability.159 
1.7 Drug utilisation review 
Drug utilisation review is a quality assurance approach for the facility per se, and it 
involves the setting of criteria and standards, an assessment phase using a set of screening 
criteria and a follow-up correctional phase with the prescriber. It comprises of all aspects 
of drug treatment from the time a patient presents to a prescriber, to the final outcome of 
the therapy.160 
Objectives of quality assurance activities 
The objectives of this activity are to ensure appropriate, safe and cost-effective drug 
therapy by achieving quality drug use and patient care. The outcomes of drug use are 
improved by161 
• determining drug usage and prescribing patterns 
• developing criteria and standards which explain optimal drug use 
• promoting rational therapy through education and by the provision of drug 
information and advice 
• carrying out regular drug use audits to evaluate the appropriateness of drug use 
and characterise inappropriateness 
• minimising the risk of adverse drug events caused by inappropriate drug use 
• promoting economical drug use by reducing wastage and unnecessary drug and 
drug related expenditure 
• providing feedback of DUE results to prescribers, managers and other relevant 
groups 
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Data sources commonly available within the hospitals are patient demographics, clinical 
and administrative data. The demographic data available such as age, sex, disease, 
average length of stay etc; clinical data such as patient charts, admission records, adverse 
drug reaction reports, microbiology/infection control data etc and finally administrative 
data such as drug purchasing, drug utilisation, equipment purchasing, utilisation and cost 
per adjusted hospital bed day data etc.162 
1.7.1 Benefits of DUE programs163 
Area of practice Percieved benefits
Hospital and government administrators Cost savings
Potential to justify expenditure/identify efficiencis
Embraces the concept of Total Quality Management
In some coountries, hospitals require a formal DUE program in place to          
acieve accrediation
Hospital pharmacists Extends opportunities for pharmaceutical care
Provides a leadership role within a multidisciplinary team
Contributes to cost justification of clinical pharmacy services
Other health proffessionals Increase potential to prevent adverse drug reactions or iatrogenic disease
Recognizes the ' added value' applied by pharmacists to the drug use          
process
Education
Patients Improved quality care
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1.8 Study Objectives 
To retrospectively evaluate Intravenous antifungal medications in paediatric patients in a 
public hospital for children. This will be achieved by retrospectively evaluating 
• Dose and the duration of antifungals prescribed 
• Infusion related reactions and adverse effects 
• Potassium level, serum creatinine and urea levels, liver function tests 
• Fever management 
• Adherence to hospital guidelines 
• Cost of antifungal treatment 
where appropriate recommendations will be made to improve patient outcomes and 
minimise hospital costs. 
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2    METHODOLOGY 
A retrospective study was conducted at Princess Margaret Hospital for Children (PMH), 
Subiaco, Western Australia a 250-bed paediatric hospital.  
2.1 Sample selection 
 All paediatric patients prescribed intravenous antifungal treatment over one year period 
(July 2006 to 30th June 2007) at PMH were evaluated retrospectively. 
2.2 Data collection 
The data related to antifungal prescribing was collected from the medical records into a 
coded prepared form. The drug charts and nursing notes were reviewed for each day in 
the records. The following data were collected for each patient prescribed IV antifungal 
drugs. Gender, age, weight, basic diagnosis, fungal infection (aspergillosis, candidiasis 
etc), dosing information, dose changes, duration of antifungal treatment, creatinine level, 
liver function tests, potassium levels, temperature, length of stay, recommencement of 
dosage of oral fluconazole and L-AmB,  infusion related reactions and adverse effects. 
Antifungal treatment costs and estimated daily cost per patient were calculated. Details of 
drug expenditure were obtained from the purchasing records of the Deparment of 
Pharmacy. Costs did not include hospitalisation costs. 
2.3 Costs of Pharmacy prepared and ward prepared IV antifungals 
The hospital pharmacy Central Intravenous Additive Service (CIVAS) and the ward 
preparation costs of antifungal infusions were determined by including the labour costs of 
pharmacists, pharmacy technicians or nurses (includes checking by a second nurse) for 
the preparation of each antifungal dose and the cost of consumables for the pharmacy. A 
2% waste of vial contents on reconstitution was also included for L-AmB. The weekend 
cost included an additional 75% Saturday and 100% Sunday loading to the normal labour 
cost calculated for the preparation. An additional estimated cost of $4 was included for 
consumables such as plastic syringes and needles. As there were only four patients on C-
AmB on different days of the year, the cost of the required vials was included. 
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Reconstituted vials must not be retained, so the cost of one vial was included for the 
doses of caspofungin and voriconazole in the pharmacy and ward setting. Costs are 
presented in Australian dollars. 
2.4 Data Analysis 
The data collected was evaluated against the Australian Therapeutic Guidelines 
Antibiotics Version 13164 and hospital in-house guidelines for antifungal therapy obtained 
from the Microbiology Department at PMH.   
2.5 Statistical Analysis 
Statistical analysis of the data was performed using the SPSS 15 statistical software 
package for windows. 
2.6 Data Storage 
Each patient was identified by a code number hence their identity remained anonymous. 
The code was maintained by the Chief Pharmacist of the Pharmacy Department  at PMH. 
2.7 Ethical issues 
The study involved the collection and analysis of patient data, therefore ethical approval 
was obtained from Curtin University of Technology Human Research Ethics Committee 
and an approval on the GEKO system (Governance Evidence Knowledge Outcome) from 
PMH which covers audit activity.  As this study involved the analysis of patient records, 
ethical issues arise in relation to confidentiality and release of data. A unique non-patient 
identifiable code was allocated to each record to enable re-identification of the record if 
necessary. The key to the code was held at all times by the Chief Pharmacist of PMH. 
Any coded data to leave the hospital was kept secure in accord with National Health and 
Medical Research Council guidelines and only group data will be released from the 
research. 
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3                                         RESULTS 
3.1  Demographic data 
The baseline characteristics of the 59 patients included in the study are presented in Table 
2. The majority of patients were male (40) and 19 female patients. All patients who were 
≤ 16 years of age were included in the study; the median age was four years (Table 3), 
the minimum age was three months and the maximum was 16 years. The mean age of the 
patients was 5.88 years, being somewhat above the median value. The median weight of 
the patients included in this study was 16.8 kg., where the weight varied from a minimum 
weight of 750 grams to a maximum of 63.6 kg. The mean weight was found to be 22.9 
kg. The doses of the antifungals were calculated according to the actual weight of the 
patients. 
Table 2  Patient gender 
Gender Number of patients(%)
Male 40 (67.8)
Female 19 (32.2)
Total 59
         
Table 3  Age and weight of the patient cohort 
Descriptive Age ( years) Weight (kg)
Minimum 0.03 0.75
Maximum 16 63.6
Mean 5.88 22.9
Median 4 16.8
Std.deviation 5.02 16.7
 
3.2 Disease diagnosed 
The principal diagnosis of the patients is summarized in the Figure 2. The most frequent 
disease diagnosed was leukaemia which constituted 28.8% of patients with acute 
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lymphoblastic leukaemia and 23.7% with acute myeloid leukaemia 6.76% of the patients 
were premature. In addition, 6.76% of patients had aplastic aneamia. Burkitts lymphoma 
and Fanconis syndrome was diagnosed in 5.08% of patients. Other diseases diagnosed in 
patients who were included in this study were myelomonocytic leukemia, febrile 
neutropenia, diaphragmatic hernia, cerebral palsy, Beckwith-Weiderman syndrome and 
congenital heart disease. 
Figure 2  Basic diagnosis of disease in patients who were prescribed IV antifungal medication 
n=59 
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Table 4  Antifungals prescribed for all patients included in the study 
 
Antifungal 
prescribed
Number of patients Percentage of patients
Voriconazole+c
aspofungin
1 1.7
L-AmB 
+voriconazole
2 3.4
L-AmB 
+caspofungin
2 3.4
Voriconazole 1 1.7
Caspofungin 2 3.4
L-AmB 47 79.7
C-AmB 4 6.8
 
3.3 Antifungal medications prescribed for principal diagnosis  
As discussed earlier, the findings of this study have indicated that L-AmB was the most 
frequently prescribed antifungal. Caspofungin, combination of L-AmB and voriconazole 
along with L-AmB were the drugs used in patients with acute myeloid leukaemia. 
Voriconazole and combination of voriconazole and caspofungin was used in the 
treatment of a patient with aplastic anaemia. Caspofungin was used in the treatment of a 
patient with acute myeloid leukeamia and fanconis syndrome and as a combination 
product. L-AmB and caspofungin was prescribed for patients with 
mucopolysaccharidosis and in prematurity. Prematurity and mucopolysaccharidosis was 
the basic diagnosis for the four patients who were prescribed C-AmB (Figure 3). Overall 
the data suggests that according to the hospital oncology ward protocol a dose of 3 
mg/kg/day of L-AmB was the dose recommended for all treatment. 
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Figure 3 Antifungal medication prescribed for the basic diagnosed disease 
 
3.4 Gender and duration of IV antifungal treatment 
 The difference in the duration of treatment of antifungal medication prescribed for all 
patients included in the study as seen in Table 5 and Figure 4. It was found that overall 
female patients had a longer duration of treatment than male patients. The median period 
of treatment was found to be 12 days for female patients and seven days for male. It was 
also seen that the minimum number of days of antifungal treatment for female patients 
was four days and two days for male patients. 
Table 5  Gender and duration of days of treatment of antifungal  
Gender (%) Minimum* Maximum* Median*
* Number of days
7
Female 
(31.1%)
4 50 12
Male 
(65.6%)
2 51
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Figure 4 Gender of the patients and the duration of treatment 
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3.5 Antifungal prescribed and the duration of treatment  
L-AmB was found to have longest treatment duration and the maximum period of 
treatment was 51 days. C-AmB was prescribed for 30, 18 and six days whereas 
caspofungin had treatment days recorded as 22 and nine days. There was only one patient 
on voriconazole and the duration of treatment was four days. The combination antifungal 
of L-AmB and voriconazole was prescribed for 17 and six days and combination of L-
AmB and caspofungin for six and four days. There was limited data on a combination of 
voriconazole and caspofungin. 
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Figure 5   Antifungal prescribed and the duration of days of treatment 
 
As shown in the above Figure 5, patients who were prescribed L-AmB had a longer 
duration of treatment which was found to be up to 51 days. It is also seen that C-AmB 
was prescribed for a longer period of time which was 30 days. Voriconazole was given 
for 4 days. All the antifungal treatments which exceeded 3 weeks were L-AmB and one 
case of C-AmB. 
3.6  Liposomal amphotericin B (L-AmB) 
Of the 59 patients who were included in this study, 47 patients were prescribed L-AmB. 
The dose of L-AmB prescribed is shown in Table 6. The mean dose was calculated for 
patients who were prescribed more than one dose of L-AmB.  From the results obtained it 
can be seen that the maximum L-AmB dose prescribed was 5 mg/kg/day and the 
minimum dose was 1 mg/kg/day which was prescribed for two patients. Interestingly, 34 
patients out of 47 were prescribed 3mg/kg/day of L-AmB. 
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Table 6  Dosages of L-AmB prescribed                    
 Dose of 
 
L-AmB 
prescribed (mg/kg/day)
2 1
1
3
1
3
1
3
1
1
3
1 3
34 3
3
5
3
5
5
3
3
5
Total 47
Antifungal 
prescribed
Number of patients
L-AmB
1
1
1
2
2
1
2
 
3.6.1 Duration of L-AmB treatment 
 The median number of days for L-AmB treatment was found to be 11 days and the 
maximum was 51 days (Table 7). A majority of patients were treated for a period 
between two and 11 days (Figure 6). 
Table 7  Duration of L-AmB treatment 
* Number of days
Minimum* Maximum* Median*
2 51 11
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Figure 6   Mean duration of L-AmB treatment 
 
3.6.2 Mean dose and duration of treatment of L-AmB below 15 days 
The dose and the duration of treatment of L-AmB are summarized in Figure 7. It suggests 
that a significantly higher proportion of patients received 3 mg/kg/day of L-AmB and the 
duration of treatment varied from two days to 15 days with a maximum of five patients 
on treatment for five days. However, there was only one patient on 1 mg/kg/day of L-
AmB given for seven days. Three of the patients received a dose of 5mg/kg/day of L-
AmB for four, nine and 15 days.  
Figure 7  Mean dose and duration of L-AmB treatment below 15 days 
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3.6.3 Mean dose and duration of L-AmB treatment above 15 days and below 30 
days 
 The results from the study (Figure 8) show that one patient received a dose of 1 
mg/kg/day of the drug for 18 days. L-AmB dosage of 3 mg/kg/day was prescribed to a 
higher proportion of patients for a period of 16 to 30 days.  
Figure 8   Mean dose and duration of L-AmB treatment above 15 days and below 30 days 
 
3.6.4 Mean dose and duration of L-AmB treatment above 30 days  
The mean dose and duration of L-AmB received by three patients is shown in Table.8. 
Two patients were prescribed 3 mg/kg/day for 32 days and the other patient on 41 days 
Table 8   Dose and duration of L-AmB above 30 days 
Number of 
patients
Dose(mg/kg/day) Number of days
2 3 32
1 3 41
 
The following Figures 9 (a-d) shows the relationship between the doses of L-AmB 
prescribed and duration of days of treatment for four patients whose mean duration was 
found to be above 30 days. There was one patient (no: 4) in this study group who was 
prescribed 7mg/kg/day of L-AmB for a period of 43 days. 
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Figure 9   Dose and duration of liposomal amphotericin B (Figure (a-d). 
Figure a. Patient no: 1        Figure b. Patient no: 2 
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Figure c. Patient no: 3                                          Figure d. Patient no: 4 
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3.6.5 Infusion related reactions reported in patients who were prescribed L-AmB 
In evaluating the overall infusion related reactions (Table 9), of the total 47 patients who   
were prescribed L-AmB, 32 (68.1%) patients were reported to have had vomiting and 
tachycardia accounted for 23 (48.9%) of the patients. Nausea was observed in 22 (48.9%) 
patients and nine (19.1%) patients were recorded with hypotension. It must be stated that 
     
35 
 
these patients were being treated with cancer chemotherapies. It would have been 
difficult to isolate the reactions only from the IV L-AmB. 
 Table 9  Infusion related reactions reported in patients who were prescribed L-AmB    
Symptoms  
observed
Symptoms  
absent
number of 
patients (%)
Number of 
patients (%)
   
Hypotension 9 (19.1) 38 (80.9) 47
Tachycardia 23 (48.9) 21 (51.1) 47
Nausea 22 (46.8) 25 (53.2) 47
Infusion related 
symptoms in patients 
prescribed L-AmB
Total number of 
patients
Vomiting 32 (68.1) 15 (31.9) 47
     
3.6.6 Adverse effects observed in patients who were prescribed L-AmB 
The overall adverse effects reported for patients receiving L-AmB is shown in Figure 10. 
All patients in this study were also on other medications. A higher proportion of patients 
developed cough (20%) followed by itchy rash (18%). Diarrhoea was observed in 16% of 
patients and 15% of patients developed abdominal pain. Additionally 13% of patients 
were reported to have sepsis and back pain was observed in 10% of patient group. 
Hypertension was less frequent and was observed in 8% of patients.  
Figure 10  Symptoms of adverse effects reported in patients concurrently on L-AmB therapy  
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3.6.7 Assesment of subsequent fluconazole commencement in patients receiving 
L-AmB. 
The overall outcome of the analysis shows that 62% of patients were restarted on 
fluconazole the day L-AmB was ceased. However, 6% of patients receiving L-AmB had 
fluconazole started after five days of cessation of L-AmB. From the data obtained from 
the records (Figure 11), it was indicated that one patient had their fluconazole dose 
started each after 24, 25, 28 and 30 days following the cessation of L-AmB. 
Figure 11  Commencement of fluconazole after cessation of L-AmB 
                                  
3.7       Conventional amphotericin B 
Out of 59 patients included in the study who received antifungal medication, only four of 
the patients were given C-AmB and all the patients were neonates whose ages are shown 
in Table 10. 
Table 10  Number of patients receiving C-AmB 
18 37 11 26
days days weeks weeks
C-AmB                           Age Total
Number of
patients
1 1 1 1 4
 
     
37 
 
3.7.1 Dose and duration of treatment of C-AmB 
From the data in Figure 12, it can be seen that 1 mg/kg/day of C-AmB was administered 
to two of the patients for a period of 18 and 30 days respectively. There was one patient 
who was given 0.5 mg/kg/day of C-AmB for six days. 
Figure 12  Dose and duration of treatment of C-AmB 
 
3.7.2 Infusion related reactions observed in patients who were prescribed C-AmB 
Of the four patients who received C-AmB during the study, there was no significant 
infusion related reactions reported as shown in Table 11. However, tachycardia occurred 
in all patients. 
Table 11  Infusion related reactions reported in patients who were prescribed C-AmB 
Infusion 
related 
reactions
Reactions observed 
(number of patients)
Total
Vomiting 0 4
Nausea 0
Tachycardia 4
Hypotension 0
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3.7.3 Adverse effects in patients who were prescribed C-AmB 
Adverse effects associated with C-AmB included hypertension, sepsis, cough and 
diarrhoea. The most frequent was that 40% of the patients had hypertension and cough. 
Sepsis and diarrhoea accounted for 20% of the patients. Symptoms of abdominal pain, 
rash and back pain were not reported in any of the four patients. These could have been 
complicated by other medications being used.                      
Figure 13  Adverse effects reported in patients who were prescribed C-AmB 
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3.8   Voriconazole 
Limited data was available for voriconazole as only one patient of the 59 was prescribed 
voriconazole (Table 12). The fungal infection was identified as aspergillosis and the 
microorganism was aspergillus fumigatus. A dose of 5 mg/kg/ day of voriconazole were 
given for a period of four days.  
There were three infusion related reactions reported to be related to voriconazole. The 
most common side effect of photophobia was observed in the patient. In addition 
tachycardia and increased respiratory rate occurred. Diarrhoea, hypertension and itchy 
rashes were also reported in this patient as adverse effects. Of note, this patient was on 
other medications and the adverse effects could be associated with them. 
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Table 12  Summary of patient data for voriconazole  
Antifungal 
prescribed
Number of 
patients
Dose(mg/ 
kg/day)         
Aspergillosis Photophobia Diarrhea
Tachycardia Hypertension
Increased 
respiratory rate
Itchy rash
Fungal 
infection
Duration of 
treatment (days)
Infusion 
related 
reactions
Adverse effects
Voriconazole 1 5 4
 
3.9    Caspofungin 
Of the 59 patients two patients received caspofungin for antifungal treatment and the data 
is shown in Table 13. The fungal infection was identified as invasive pulmunory 
aspergillosis. One patient received 1.2mg/kg/day of caspofungin for 22 days and the other 
patient 1.8 mg/kg/day for nine days. Infusion related reactions reported were nausea, 
vomitting, and hypotension. Identified as an adverse effect related to caspofungin, cough 
occurred in both patients. Other adverse effects reported related were sepsis, itchy rash, 
abdominal pain, respiratory distress and diarrhoea. 
Table 13    Summary of caspofungin data 
Antifungal 
prescribed
Dose(mg/kg/ 
day)
1.2 22 Nausea Cough
Vomitting Sepsis
Hypotension Respiratory distress
Itchy rash
Cough
1 18 Nausea Abdominal pain
vomitting Diarrhoea
Adverse effects
Caspofungin 2 Invasive 
pulmunory 
aspergillosis
Number 
of 
patients
Fungal 
infection
Duration of 
treatment(days)
Infusion related  
reaction
 
3.10       Combination antifungals 
Details of antifungal combination treatment are summarized in Table 14. It was found 
that L-AmB was combined with caspofungin and voriconazole as combination 
antifungals. Of the 59 patients included in the study, five received combination 
antifungals. Two patients were prescribed a combination of L-AmB and caspofungin and 
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the infusion related reactions reported were tachycardia, nausea, vomiting and 
hypotension. Adverse effects such as diarrhoea, hypertension, sepsis and cough was 
observed in the patients. A combination of L-AmB and voriconazole was prescribed for 
three patients and the infusion related reaction related to voriconazole, photophobia 
occurred in these patients along with vomiting, nausea, hypotension, sepsis, severe cough 
and respiratory distress. Itchy rashes and abdominal pain occurred in these patients. There 
was one patient who received a combination of caspofungin and voriconazole 2.5 
mg/kg/day for duration of four days. No significant infusion related reactions were 
reported except vomiting. Cough and sepsis occurred in the patient as side effects. Of 
note, all the patients were on other medications as well as the antifungals. 
Table 14  Summary of combination antifungal treatments 
Antifungal 
prescribed
Number of 
patients
Infusion 
related 
reaction
Adverse 
effects
L-AmB + 1
Caspofungin
L-AmB + Vomitting Sepsis
Voriconazole Nausea Severe cough
Hypotension 
Photophobia    
Respiratory 
distress
 Itchy rashes
Abdominal 
pain
Caspofungin+ Cough
voriconazole sepsis
Tachycardia Diarrhoea
3
1 Vomiting
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Figure 14  Dose and duration of combination antifungal treatment (fig e-i) 
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Figure f: Patient 8 
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Figure g: Patient 9 
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Figure h: Patient 10 
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Figure i: Patient 11 
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Figure 15  Adverse effects reported in patients who were prescribed combination antifungal 
treatment. 
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Overall the results suggest that nausea and vomiting occurred more frequently in patients 
who received combination antifungals. And also, a significantly higher proportion of 
patients developed cough followed by sepsis (Figure 15). This may have arisen from the 
severity of the infections. 
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3.11    Antifungal medication prescribed for neonates 
 Of the 59 patients included in the study who were prescribed antifungal mdication, nine 
were neonates. As discussed earlier, four patients were given C-AmB (Table 15).  Two 
patients received L-AmB 3mg/kg/day for 22 days for one patient and the other patient for 
14 days. A combination of L-AmB with caspofungin was received by one patient with a 
dose of 0.5 mg/kg/day.  
Table 15  Dose and duration of antifungals prescribed for neonates 
Number of 
neonates
Antifungal 
prescribed
Dose 
(mg/kg/day)
Duration of 
treatment(days)
3 22
3 14
0.5 6
0.5 6
1 18
1 30
Combination of
L-AmB + 
voriconazole
L-AmB 1 9
3 18
8 48
Voriconazole 5 3
1
2 L-AmB
4 C-AmB
 
3.12 Infusion related reactions and adverse effects 
Tachycardia occurred in two patients and one patient had vomiting as infusion related 
reactions. No other infusion related reactions were reported. Hypertension and cough 
occurred in two patients and no other adverse reactions were observed.  
 
 
 
     
45 
 
Figure 16   Mean dose and duration of antifungal prescribed for neonates 
 
3.13 Potassium, liver function, creatinine and temperature data 
3.13.1  Potassium levels in patients who recieved L-AmB 
The overall potassium level data for all patients included in this study who received L-
AmB are shown in Figure 17. The result suggests that 73% of the patients had a normal 
potassium level and that 27% of patients had a low potassium level. Normal potassium 
level for each patient varied according to the patients.  
Figure 17  Potassium level data for all patients who were prescribed L-AmB 
 
3.13.2   Liver function tests (n = 59) 
Data for liver function tests for all the patients included in the study are summarized in 
Figure 18. The normal levels of all the elements are shown in the Table 16. A 
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significantly higher proportion of patients receiving antifungal were found to have 
abnormal ALT and abnormal AST. Overall the albumin levels were found to be normal. 
Table 16  Normal level data for liver function tests 
AST (µ/L) <60
ALK (µ/L) 100-350
Bilirubin (µmol/L) <20
ALT (µ/L) <30
Element Normal  level
Albumin (g/L) 32-48
 
Figure 18  Results of liver function tests for the patient cohort 
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3.13.3 Creatinine and urea level 
In evaluating the data for serum creatinine and urea, listed in Table 17, it was found that 
11(18.6%) out of the 59 patients had abnormal serum creatinine levels. In addition the 
antifungal used in patients with abnormal creatinine levels were found to be six patients 
on L-AmB and four patients receiving combination drug of L-AmB with caspofungin and 
voriconazole. There was also one patient on voriconazole. 16 (28.6%) of 59 patients were 
found to have high urea levels and the antifungals recieved were L-AmB (n=15) and a 
combination of L-AmB and caspofungin. 
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Table 17  Summary of serum creatinine and urea level 
 
3.13.4    Creatinine clearance data 
Creatinine clearance for all the patients whose serum creatinine level was high was 
calculated and is summarised in Table 18. All patients who had lower creatinine 
clearance levels were also on other medications which could increase serum creatinine 
clearance. Cyclosporin and diphenhydramine which affects creatinine clearance were 
found to be the most frequently prescribed drugs among the patients whose serum 
creatinine level was high. The second most frequent drug was cyclosporin followed by 
other drugs.  
3.14 Temperature data of patients during antifungal treatment 
During the period of antifungal treatment there was a reduction in the temperature level 
of patients from the day the antifungal was commenced until the cessation of antifungal 
treatment. The mean temperature of the patients is summarized in the Table 19. It was 
found that the mean temperature at the start of antifungal treatment was 38.3˚C   and at 
the cessation of antifungal treatment the temperature has reduced to 37.0˚C. 
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Table 18  Creatinine clearance and the other medications which increases serum creatinine level 
Age  
(years)
Creatinine 
clearance 
(mL/min)
Antifungal  
prescribed
Dose(mg/kg    
/day)
Other medications
which increase serum
creatinine level while
on ambisome
cyclosporin
diphenhydramine
acyclovir
fluconazole
cyclosporin
diphenhydramine
acyclovir
fluconazole
cyclosporin
diazepam
ciprofloxacin
Vancomycin
Loratidine
LAmB+ 
voriconazole       
3 lorazepam
5 oxycodine
3 fluconazole
acyclovir
5 diphenhydramine
cyclosporin
methylprednisolone
LAmB+ 
voriconazole       
3 ciprofloxacin
8 fluconazole
3 vancomycin
5 acyclovir
70.1
6 11 156.5 149 51.4
5 9 127.5 89
56.0 L-AmB 3
4 3 98.0 56 85.7 L-AmB 3
3 16 163.5 143
33.1 L-AmB 3
2 7.5 110.5 114 47.4 L-AmB 3
Patient Height 
(cm)
Serum 
creatinine 
(µmol/L)
1 16 152.0 225
 
Table 19   Mean temperature of patients at the start and at the cessation of antifungal treatment 
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Start of antifungal
treatment
Cessation of 
antifungal
 treatment
35.5 39.8 38.3
35 38.5 37
Measurement Minimum (0C) Maximum (0C) Mean (0C)
 
Figure 19  Mean temperature data at commencement and cessation of antifungal treatment 
Fever management during antifungal treatment
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3.15 Days of the week when the IV antifungal treatment were changed or 
ceased 
The major ward rounds are scheduled for a Tuesday and Thursday. Decisions on the 
change of antifungal dose or the timing of cessation of the antifungal are made at the 
rounds. Changes can be made by physicians in the ward. It is seen from the results in 
Table 19, that the majority of the changes made in antifungal dose in the ward were on 
Thursdays (43.5%) followed by on Tuesdays (21.7%). On the other hand cessation of 
antifungal treatment was found to occur on Wednesdays (22.7%) and Fridays (21.3%) 
and also it was noted that 17.3% and 16% of patients had their antifungal course stopped 
on Tuesdays and Thursdays respectively. Notably few patients had their antifungal 
treatment changed or ceased on Saturdays, Sundays or Mondays. 
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3.16   Cost of antifungal treatment in the hospital 
The costs of the antifungals were obtained from the Pharmacy Department. For L-AmB, 
amounts above 100 mg used in the preparation, the time involved included the cost of an 
extra two minutes for addition of each vial to the labour cost of Pharmacist, Pharmacy 
technician and the nurse (Table 21 & 22). 
Table 20  Days of the week when the antifungal dose was changed and ceased. 
Change of 
antifungal 
dose(n=23)  
(%)
Saturday 4.3 8.0
Sunday 4.3 2.7
Thursday 43.5 16.0
Friday 13.0 21.3
Tuesday 21.7 17.3
Wednesday 8.7 22.7
Days of 
treatment
Cessation of 
antifungal 
treatment 
(n=59) (%)
Monday 4.3 12.0
 
Table 21  Cost of antifungal drugs in AUD 
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Liposomal
amphotericin B (50 
mg vial)
 Conventional 
amphotericin B
50 mg vial
Voriconazole
200 mg  vial
Caspofungin
50 mg vial
729.4 Per vial cost
24 Per vial cost
190.84 Per vial cost
Antifungal Cost($) 1 mg(including 2% 
wastage on 
reconstitution)($)
268.5 5.5
 
 
 
 
Table 22  Total labour and consumable costs for preparing L-AmB 
Pharmacy Ward Pharmacy Ward
 prepared 
cost
prepared 
cost
 prepared 
cost
prepared 
cost
($) ($) ($) ($)
23.54
Sunday 18.19 23.25 20.99 26.05
Saturday 16.58 21.1 19.02
101-150(mg)
Weekdays 11.74 14.5 13.14 15.9
Days   1-100(mg) 
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Pharmacy Ward Pharmacy Ward Pharmacy Ward
 prepared 
cost
prepared 
cost
 prepared 
cost
prepared 
cost
 prepared 
cost
prepared 
cost
($) ($) ($) ($) ($) ($)
31.65 29.39 34.45Sunday 23.79 28.85 26.59
18.7 17.34 20.1
Saturday 21.46 25.98 23.9 28.42 26.34 30.86
Weekday 14.54 17.3 15.94
Days   151-200 (mg) 201-250(mg) 251-300(mg)
 
Table 23  Examples of treatment costs of L-AmB received by the patients 
Pt Age Wt Dose Mg/kg/day
No: (years) (kg) (mg)
Pharmacy Ward Pharmacy Ward Pharmacy Ward Pharmacy Ward
prepared 
cost($)
prepared 
cost
prepared 
cost($)
prepared 
cost
prepared 
cost($)
prepared 
cost
prepared 
cost($)
prepared 
cost
($) ($) ($) ($)
75 3 424 553 3,063 4,009 6,126 8,019 9,189 12,090
128 5 717 823 5,118 5,904 10,327 11,808 15,377 17,733
178 3 993 1,093 7,072 7,812 14,145 15,625 21,218 23,438
296 5 1,645 1,633 11,659 11,615 23,319 23,231 34,979 34,847
                                                   Cost  ($)
                                               Number of days
1(weekday) 7 14 21
553 2,6011 4 21.2 63 12,029
2 4 25.5
4,009 5,202 8,019 7,8033 358
3 16 59.1
4 16 53.5 160 3 894 1,093 6,379 7,812 12,759 15,625 19,139 23,438
 
3.17 Treatment costs of L-AmB received by the patients 
Costs per patient were calculated by taking into account costs per mg (based on the 2008 
prices provided by the hospital pharmacy) multiplied by the number of prescribed doses 
and the number of days of treatment and adding the labour cost in pharmacy and in the 
ward setting. Random patients were selected for calculation of costs as shown in the 
above (Table 23) in calculating a general average total treatment cost on a weekly basis. 
Overall the treatment cost in the ward setting was higher. It is clearly demonstrated that 
treatment cost of the antifungal depends on the body weight and therefore the size of the 
dose administered to the patients. For a patient (no: 4), of 16 years with a body weight of 
53.5 kg, the estimated pharmacy prepared and ward prepared cost were found to be 
$19,139 and $23,438 respectively for antifungal treatment for 21 days. The difference is 
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mainly due to the required cost of four vials for a 160 mg of L-AmB in the ward setting 
whereas in the pharmacy setting the cost was calculated on a per mg basis. 
Table 24  Total treatment cost for patients who received L-AmB   for more than 30 days 
Age Weight Dose
(years) (kg) (mg)
Pharmacy 
prepared
Ward 
prepared
45 3 3 812 905
15 1 37 3,977 11,254
60 3 30 10,649 17,179
20 1 18 2,425 5,467
35 3 33 7,172 9,960
12 1 11 906 3,014
45 3 10 2,992 3,313
80 8 18 7,913 10,316
85 8 30 14,774 17,179
180 3 7 7,149 7,812
290 54 21 34,286 34,847
174 3 3 2,958 3,338
43 11 57.7 31
99 1.5 11.8 102
21 4 20.7 48
40 2 14.74 40
Number 
of days
       Treatment cost
                  ($)
Total 
number 
of days
Patient 
number
Mg/kg
 
 
 
Table 25  Total treatment cost for patients receiving L-AmB   for more than 30 days 
Pharmacy 
prepared
Ward 
prepared
Pharmacy 
prepared
Ward 
prepared
Pharmacy 
prepared
Ward 
prepared
Pt:no Total treatment cost                  
($)
Total cost/day             
($)
Treatment cost in 
excess of 21 days ($)
40 4,790 12,159 119 303 2,275 5,775
21 13,074 22,646 272 471 7,626 13,210
99 34,222 43,784 335 429 27,106 34,770
43 44,394 45,998 1,432 1,483 14,320 14,838
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Table 26   Cost estimates for patients receiving L-AmB   for more than 30 days 
Pharmacy 
prepared 
cost($)
Description Ward 
prepared 
cost ($)
Difference in 
ward and 
pharmacy 
prepared cost 
($)
Mean cost/ day 539 672 132
Total treatment 
cost for 4 patients 
on L-AmB for 
more than 30 days
96,482 124,702 28,220
Cost for > 21 days 51,329 68,594 17,265
Savings 45,152 56,107 10,955
 
3.18 Cost estimates for patients receiving L-AmB   for more than 30 days 
The estimated cost of the four patients (4/59) who received L-AmB where it was 
prescribed for a period of more than 30 days is shown in Table 25. Patient (no:99) 
received L-AmB for a period of 102 days which was the longest duration of antifungal 
treatment in this study period. The estimated cost for the treatment was found to be 
$34,222 if pharmacy prepared and $43,784 if prepared in the ward setting. The treatment 
cost for more than 21 days which was 81 days, $27,106 or $34,770 for pharmacy and 
ward prepataion respectively. When compared with patient number 43 who received 
antifungal treatment for 31 days provided higher estimated total costs of $44,394 and 
$45,998 for the pharmacy and ward settings respectively. This could be explained by the 
body weight of this patient with an estimated cost per day of $1,432 and $1,483 in 
pharmacy and ward settings respectively. On calculating the mean cost, table 24 clearly 
depicts that on an average cost per day for each patient was found to be $539 and $672 in 
pharmacy and ward setting and  that a mean cost of  $132 could be saved each day if the 
antifungals were prepared in pharmacy CIVAS. Overall a total cost of $28,220 could be 
saved for all the four patients included in this study who received L-AmB for more than 
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four weeks. In addition, if the antifungal treatment was ceased at an optimum duration of 
three weeks $45,152 and $56,107 could have been saved in pharmacy and ward setting 
and also an additional $10,995 could be saved if prepared in pharmacy setting. 
Table 27   Treatment cost of C-AmB received by the patients 
Pt. Age Weight Dose
no: (weeks) (kg) (mg)
Pharmacy 
prepared
Ward 
prepared
1 30 1,469 1,78943 26 3.8 3.8
1 18 877 1,06642 11 3.4 3.5
0.5 6 289 35140 2.5 1.3 0.5
Mg/kg Number 
of days
 Treatment Cost
($)
 
Table 28   Treatment cost of voriconazole received by the patient 
Age Weight Dose
(years) (kg) (mg)
Pharmacy 
prepared
5 4 810 82921 4 21.3 106
Pt no: Mg/kg Number 
of days
     Total  Cost
             ($)
Ward 
prepared
 
  Table 29   Treatment cost of caspofungin received by the patients 
Weight 
(kg)
Dose 
(mg)
Pharmacy 
prepared
Ward 
prepared
Pharmacy 
prepared
Ward 
prepared
45 1 10 7,422 7,478
50 1 9 6,681 6,783
22 16,338 16,466
14,104 14,262
55 16 40.2 50 0.8 22 16,338 16,466
79 14 45.1 19
 Treatment Cost ($) Total 
number 
of days
Total  treatment       
cost($)
Pt no: Age 
(years)
Mg/kg Number 
of days
 
3.19 Treatment cost of Voriconazole and Caspofungin 
Of the 59 patients included in this study four, one and two patients received C-AmB, 
voriconazole and caspofungin respectively. Among all the antifungal medication 
prescribed in this study, caspofungin was the most expensive drug. From Table 28, it can 
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be seen that the total treatment cost for patient 55 was $16,338 and $16,466 in the 
pharmacy and ward setting. The cost of one vial was calculated in both pharmacy and 
ward setting and the difference between the costs was the labour cost in pharmacy and 
ward setting. Unfortunately voriconazole was prescribed to only one patient during the 
study period and the cost of one vial was calculated for both ward and pharmacy setting 
and the total treatment cost for 5 days was found to be $810 and $819 in the pharmacy 
and ward setting respectively. 
During the study period 4/59 patients received combination antifungals as a part of the 
antifungal regimen and the treatment cost for each of the antifungals is summarised in 
Table 28. The highest cost estimated was for patient 85 with a body weight of 40.2 kg on 
200 mg of L-AmB for a period of 26 days was found to be $29,404 and $35,983 for 
pharmacy and ward setting respectively. For 290 mg of L-AmB prescribed for patient 
five with a body weight 58.4 kg, the treatment cost for 11 days was the next highest cost 
which was estimated to be $17,885 or $18,175 in pharmacy and ward setting preparation. 
Caspofungin with an amount of 35mg was prescribed for a period of four days and the 
estimated cost was $3,011 and $3,030 for the pharmacy and ward setting respectively. 
 
 
Table 30   Cost for antifungal treatment when a combination was included as a part of the 
antifungal regimen  
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Weight Dose Mg
(kg) (mg) /kg
Pharmacy 
prepared
Ward 
prepared
L-AmB 180 3 3 3,040 3,321
 L-AmB 290 5 11 17,885 18,175
voriconazole 175 3 10 2,069 2,125
L-AmB 165 3 7 6,552 7,793
L-AmB 160 3 11 9,970 12,213
L-AmB 50 3 7 2,055 2,130
L-AmB 15 1 16 1,718 4,863
L-AmB 45 3 4 1,083 1,206
Caspofungin 35 2 4 3,011 3,030
L-AmB 80 5 4 1,853 2,280
L-AmB 200 5 26 29,404 35,983
voriconazole 190 4 10 2,069 2,125
L-AmB 12 1 11 995 3,337
L-AmB 45 3 10 2,721 3,035
L-AmB 80 8 17 8,365 10,300
Voriconazole 45 4 38 10,353 11,556
L-AmB 85 7 30 14,774 17,179
85 16 40.2
99 1.5 11.8
5 13 58.4
80 4 16.2
Age 
(years)
Antifungal 
prescribed
Number 
of days
     Treatment cost
          ($)
Patient 
no:
 
Table 31 Total cost for antifungal treatment when a combination was included as a part of the 
antifungal regimen 
Pharmacy 
prepared
Ward 
prepared
Pharmacy 
prepared
Ward 
prepared
347 42490 107 37,210 45,407
277 386
85 36 31,474 38,108 874 1,058
80 35 9,722 13,512
Treatment cost/day
($)
5 42 39,519 43,630 940 1,038
Patient 
number
Total 
number 
of days
Total treatment cost
($)
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Table 32   Cost estimates for antifungal treatment when a combination was included as a part of 
the antifungal regimen 
Pharmacy 
prepared
Total cost for 
4 patients on 
combination 
antifungal
117,927 140,659 28,220
Difference in 
ward and 
pharmacy 
prepared cost 
($)
Mean cost/ 
day
610 726 116
Description Ward 
prepared 
cost($)
 
3.20 Cost estimates for antifungal treatment when a combination was 
included as a part of the antifungal regimen 
Total cost for antifungal treatment when a combination was included as a part of the 
antifungal regimen for all four patients who received antifungal treatment is shown in 
Table 30. The mean cost per day for antifungal treatment in the pharmacy prepared 
setting was estimated to be $610 and at the same time in the ward setting the treatment 
cost per day was found to be $726 (Table 31). In addition, a daily treatment cost of $116 
could be saved if the antifungals were prepared in the pharmacy CIVAS. In calculating 
an estimated total cost for the four patients, $117,927 accounted for the pharmacy 
prepared setting and $140,659 for the ward prepared setting. A total treatment cost of $ 
28,220 could be saved when prepared in the pharmacy CIVAS. 
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4     GENERAL   DISCUSSION 
Many advances in the development of antifungal agents have been made in the past 
decade. Whilst remarkable advances in the treatment of IFIs have been reported with the 
availability of extended-spectrum triazoles and echinocandins, the mortality rate from 
infections remains high.115  
The currently available antifungal therapies exhibit limited effectiveness and a complete 
response depends on correction of the underlying disease.165 Based upon both large 
prospective clinical studies, the intensification of transplant procedures and antineoplastic 
therapy has been enabled by stringent guidelines for the early diagnosis of infections and 
systematically escalated antifungal treatment.166  
4.1 Study population 
The current study population included mainly patients diagnosed with acute leukaemia. 
Despite the lengthy study period, the overall number of patients, which was a census 
population, was rather small. It was interesting to note that, as at Duke university 
Hospital where L-AmB was used in 70% of the cases in the treatment of documented 
infections, in this study L-AmB was given more often and accounted for 79.7% of study 
population.167  This was not entirely unexpected since L-AmB remains the gold standard 
for the treatment of many invasive fungal infections in adults and in children as well as 
the comparative agent for all newer antifungal agents.2  
4.2 Treatment with L-AmB 
In a retrospective audit of L-AmB use carried out in the USA, because of problems 
associated with a lack of consensus on dose and duration of treatment for certain 
infections and the clinical diagnosis of fungal infections, no attempt was made to 
determine whether antifungal drugs has been used correctly.167 Consequently, the current 
study attempted to assess whether IV antifungal drugs were used according to current 
accepted clinical practice in a paediatric setting. 
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For the current study, drawing firm conclusions for all antifungals was impossible due to 
an insufficient sample size for the patients who received antifungals other than L-AmB. 
These were voriconazole, caspofungin and C-AmB. During the current study period it 
was noted that a single dose of 3 mg/kg/day of L-AmB were received by 34 patients out 
of the 47 patients who were prescribed L-AMB which is the standard dose recommended 
by the Antibiotic Therapeutic Guidelines.164 Some investigators have examined the use of 
low-dose of IV L-AmB (ranging from 0.5 mg/kg/day to <0.1 mg/kg/day) for prophylaxis. 
In a retrospective analysis, both the incidence of transplant related mortality and invasive 
aspergillosis was decreased. However due to the presence of confounding environmental 
and prognostic factors and the use of historical controls, these results were 
inconclusive.168, 169 There was an encouraging trend towards a reduced incidence of IFIs 
in patients receiving chemotherapy and in haematopoietic stem cell transplantation 
recipients observed in  two double-blind placebo controlled studies using L-AmB  at 1 
mg/kg/day or 2 mg/kg/day three times weekly for prophylaxis.170, 171 
4.3 Duration of L-AmB treatment 
In the current  study, the results demonstrated that the median duration of therapy with L-
AMB were 11 days and the median dose was 3 mg/kg/day unlike the results from a study 
conducted by Wiley et al.,172 where the median duration was 15 days and the median 
dose was 5 mg/kg/day. No firm recommendation regarding the optimal duration of 
antifungal prophylaxis can be given in the absence of adequate trials.173 
4.4 L-AmB for prophylaxis 
The findings from the current study demonstrated that 1 mg/kg/day of L-AmB were 
given more often in the hospital for prophylaxis or empirical therapy. This was not 
entirely unexpected since management of  neutropenic and febrile patients prophylaxis 
has become conventional practice.174 The use of antifungal prophylaxis results in the 
selection of naively resistant organisms as it  has the potential for induction of resistance 
potentially leading to a change in the epidemiology of fungal infections, which has been 
pointed out by several reports.173 
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With the use of prophylactic L-AmB in children undergoing intensive chemotherapy for 
AML, using historical controls the preliminary study of Ritter175 demonstrated an 
apparent dramatic reduction in the incidence of SFI. A blinded and randomised study 
from Sweden171 compared L-AmB dosage of 1 mg/kg/day with placebo. Of the 36 
patients who received L-AmB and 40 placebos in well balanced groups, the fungal 
colonisation increased in follow up in the placebo group (41-62%) and decreased in the 
L-AmB group (55-33%). In one patient receiving L-AMB and three receiving placebo 
proven fungal infection occurred. This trial demonstrated that prophylactic L-AMB was 
well tolerated and effective.  
4.5 Dosage of L-AmB 
The maximum dose of L-AmB treatment received by the patients in the current study 
group was 10 mg/kg/day followed by 8 and 7 mg/kg/day. In another study, a randomised 
trial of two doses (1 vs. 4 mg/kg/day) of L-AmB was carried out by the EORTC 
antifungal group in the treatment of probable and proven aspergillosis.176 There were 
eight proven SFI on L-AmB 1 mg/kg/day and 12 on 4 mg/kg/day and 33 probable cases 
versus 34 probable on the 1 and 4 mg/kg/day doses respectively. The outcome of the trial 
showed no advantages for the higher dose of L-AmB and in addition, there were more 
proven cases on the 4 mg arm. But the chances of missing an advantage with these 
numbers were high. Thus, optimal dosage for various clinical situations must remain an 
open question.19 
No dose related trends in adverse effects were observed in a pharmacokinetic study of L-
AmB conducted in 39 children ranging in age from one to 17 years and also a maximally 
tolerated dose of 10 mg/kg/day.177 A prospective study evaluated the safety and efficacy 
of L-AmB administered to 260 adults, 242 children (<15 years) and 43 infants (< 2 
months of age). The largest doses of L-AmB administered for the longest period of time 
were well tolerated by the infants and children, again suggesting that L-AmB is well 
tolerated in paediatric patients and better generally than the older patients.178 
In children undergoing chemotherapy, the safety of weekly high doses of L-AmB has 
been confirmed recently.179 The relevance of high dose regimens of L-AmB in the 
prophylaxis of fungal infections suggested by the pre-clinical and pharmacokinetic 
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studies supported this new therapeutic approach. This approach could decrease the 
expenditure on antifungal agents.180 In patients with IFI,  dosages of L-AmB as high as 
15 mg/kg/day were well tolerated (despite a relatively high rate of hypokalemia) with an 
AUC maximised at 10 mg/kg/day.181 The occurrence of adverse effects could have been 
favoured by factors specific to the SCT patients. The recommendations for antifungal 
treatment issued by the European Agency for Evaluation of Medicinal Products have 
underlined the difficulties related to safety evaluation of antifungal treatments. Indeed 
owing to the numerous concomitant medications and serious underlying conditions, it is 
difficult to establish the drug-relatedness of adverse affects in such patients.182 In a recent 
pilot study,183 21 SCT recipients who received 7.5 mg/kg/day of L-AMB, side effects 
were not observed. A clinical study in young children by Mehta et al.184 investigated the 
pharmacokinetics of once weekly high dose of L-AmB therapy. It was found that L-AmB 
was well tolerated and was measurable in plasma seven days after a high dose infusion 
and was near the minimum inhibitory concentration for susceptible strains.  
In the UK, a trial170 in patients undergoing chemotherapy was carried out. 74 patients 
received L-AmB 2 mg/kg three times weekly and 87 patients had placebo. None of the 
patients on L-AmB had proven systemic fungal infection after the treatment however, 
three (3.4%) on placebo had. In 40% of patients on placebo and 20% on L-AmB, fungal 
colonisation occurred. Compared to placebo, no excess toxicity was reported with L-
AmB.  
4.6 Adverse effects observed with the use of L-AmB 
 For dose escalation or prophylactic therapy, L-AmB is probably the only antifungal 
agent which can reasonably be considered because of the reduced toxicity.19 The results 
from the current study demonstrated that 32 out of 49 patients (68.1%) during the study 
period were reported to have had vomiting during infusion followed by tachycardia 23 
(48.9%) and nausea 22 (46.8%). It is more difficult to establish adverse effects in patients 
receiving numerous concomitant medications. The Walsh study177 demonstrated that 
there was a clear advantage for L-AmB with a highly significant reduction in the 
incidence of chills rigors, fevers and other reactions including hypotension, tachycardia, 
hypertension, dyspnoea compared to other antifungal agents.19 Infusion related and 
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adverse reactions in this study were recorded from the nurse’s daily notes. However, the 
symptoms were not described under any category whether it was infusion related or 
adverse effects.  
4.7 Limitations of C-AmB         
Conventional amphotericin (C-AmB) was received only by four out of 59 patients during 
the current study period. It was also interesting to note that all four patients were below 
one year of age. Clinical use of C-AmB is limited by a number of factors. (a) Serum drug 
concentrations are comparatively low at standard doses (1.0 mg/kg/day) of C-AmB185 (b) 
Since the drug extensively binds to cholesterol containing cell membranes the 
bioavailability of C-AMB in organ tissue is small.186,187 (c) Considerable acute and 
chronic toxicity limits the tolerability of C-AmB, which may necessitate dose reduction 
or cessation of treatment. In fact, C-AmB dose escalation is limited to a daily dose of 1.5 
mg/kg/day.188 
4.8 Adverse effects of C-AmB 
Compared to L-AmB, the use of C-AmB however, is complicated by a high incidence of 
potentially serious side effects.189, 190  As discussed earlier, all the four patients receiving 
C-AmB were neonates which could be the reason no infusion related reactions were 
recorded. However, it was noted that tachycardia occurred in all four patients. 
Hypertension was observed in 40 % of the patients as an adverse effect and it was 
important to note that all patients in this study group were on other concurrent 
medications. It is particularly important to note from the results from a comparative study 
between L-AmB and C-AmB by Walsh et al.177 the values for hypertension (L-AmB 
2.3%, C-AmB 11.3%) tachycardia (L-AmB 2.3%, C-AmB 12.5%), hypotension (L-AmB 
3.5%, C-AMB 8.1%) and hypoxia (L-AmB 0.3%, C-AmB 6.4%). There were 
significantly less prevelance of adverse effects with L-AMB and of note is a 5.8% 
evidence of dyspnoea with L-AmB compared with 10.8% with C-AmB.  
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4.9 Comparison of L-AmB and C-AmB 
The pharmacokinetics of amphotericin B have been greatly altered by the lipid 
formulation. However, it remains unclear to what extent there is a relationship between 
the clinical efficacy and pharmacokinetics of L-AmB. Increasing the dosage will result in 
greater concentrations of amphotericin B in tissue as indicated by the preclinical data 
obtained with mice191 as well as data obtained from L-AmB treated patients. It still 
remains to be shown if an equivalently greater antifungal activity can be translated by the 
significantly greater C max and AUC values of L-AmB. It may be concluded from 
preclinical experience that a dose increase from 1 to 3 mg/kg does not significantly 
increase treatment associated side effects of L-AmB. An L-AmB dose of 3mg/kg is 
presently recommended.192 
4.10 Treatment with voriconazole 
In the current study, a voriconazole dose of 5 mg/kg/day was received by only one patient 
for a period of four days and the infusion related reactions of photophobia, tachycardia 
and dyspnoea were reported. Diarrhoea, hypertension and itchy rashes were also reported 
as adverse effects in these patients who received voricaonazole. The fungal infection was 
identified as aspergillus. It was difficult to establish any conclusions from this study for 
voriconazole as only limited data were available since the sample size was just one 
patient. 
Because the pharmacokinetics in paediatric patients are linear, children require higher 
doses of voriconazole than adults to attain similar serum concentrations over time.2 The 
results from limited pharmacokinetic analyses92 have demonstrated that a paediatric dose 
of approximately 11 mg/kg administered every 12 hours was approximately 
bioequivalent to an adult dosage of 4 mg/kg/day given every 12 hours. The authors 
recommended a higher doses of voriconazole though unproven in large controlled clinical 
settings.92 
 For the treatment of invasive aspergillosis, voriconazole has become the drug of choice 
and the change for primary therapy of aspergillosis from amphotericin B to voriconazole  
followed the publication of a large multinational randomised trial that compared 
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amphotericin B with voriconazole in 277 patients with probable or proven  
aspergillosis.134 It was found that 53% of the voriconazole group and 32% of the 
amphotericin B group had complete or partial responses at week 12. Patient survival was 
71% in the voriconazole group and 58% in the amphotericin B group. These results 
supported the fact that for initial therapy for patients with invasive aspergillosis, 
voricaonazole was more effective than amphotericin B. 
Voriconazole also was an effective therapy for candidiasis. Approximately 40% of 
patients  treated with voriconazole in a study of 422 patients with invasive candidiasis.135 
Reversible dose dependent visual disturbances (increased brightness, blurred vision) were 
the most frequent side effect of voriconazole in as many as one third of treated 
patients.193 Liver function abnormalities, skin reactions likely due to photosensitisation, 
fever and digestive track events were the other side effects reported.194  
4.11 Treatment with caspofungin 
Reports from the current study demonstrated that caspofungin dosage of 1.2 mg/kg/day 
and 1.8 mg/kg/day was prescribed to a patient who was diagnosed with invasive 
pulmonary aspergillosis. Unfortunately, information regarding caspofungin was limited 
as well as there were only two patients out of the 59 patients in this study period who 
received caspofungin. However, these results were similar in many aspects to other 
reports on caspofungin. 
An FDA approved clinical study on 56 patients with acute invasive aspergillosis used 
caspofungin as salvage therapy and it was found that more than 40% of the patients had a 
favourable response to therapy.71 A pharmacokinetic study was conducted in children on 
a basis of weight (1 mg/kg/day) and body surface area (50 or 70 mg/m2/dy) in 39 patients 
between the ages two and 17 years. The results suggested that the weight based approach 
resulted in sub-optimal plasma concentrations, whereas the body surface area  approach 
yielded similar plasma concentrations when compared to plasma concentrations attained 
in adults treated with 50 mg/day.195 
To date, the use of caspofungin in patients with severe hepatic insufficiency has no 
clinical experience. The maximum tolerated daily dose of caspofungin in patients is not 
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known. In healthy subjects, caspofungin continues to be well tolerated at single doses up 
to 210 mg/day and multiple doses up to 100 mg/day.196 
A randomised double blind, comparative study for the empirical use of caspofungin in 
febrile neutropenic patients showed it was as efficacious as L-AmB in preventing 
breakthrough fungal infections and in treating baseline fungal infections. Caspofungin 
was superior to L-AmB and also was better tolerated with fewer side effects.197 Another 
randomised double blinded study compared caspofungin with amphotericin B 
deoxycholate and demonstrated that the efficacy of caspofungin was similar to  
amphotericin B deoxycholate for the primary treatment of invasive candidiasis.198 
Patients treated with caspofungin had fewer drug related adverse events than those treated 
with C-AmB (20.2% vs. 48.8%)198 and L-AmB (35.1% vs. 51.6%).197 Data on the range 
of usefulness and efficacy of caspofungin in children with IFIs is limited to case series 
data and case reports, though there is  pharmacokinetic data to show the importance of an 
increased (higher) dose of caspofungin in a child vs. adult patient.2 
4.12 L-AmB and fluconazole 
From the results obtained from the current study, it could be seen that the oral 
administration of fluconazole was stopped during the  treatment with L-AmB and L-AmB 
and fluconazole was not given concomitantly, a practice which is considered both 
unorthodox and controversial.188,199 However, it was found that 38% of the patients who 
received L-AmB did not have their fluconazole drug started the day L-AmB was ceased. 
The combination of antifungal agents may lead to antagonism or increased toxicity by 
decreasing the ability of agents to exert their competitive action on the same target 
(proposed for amphotericin B and azoles).200 Lewis et al.201 suggested that there was no 
interaction on simultaneous administration of amphotericin B and fluconazole, whereas 
sequential administration (fluconazole exposure before amphotericin B) resulted in a 
substantial decrease in amphotericin B fungicidal activity.           
4.13 Combination antifungal treatment 
The combination drugs given in this study were L-AmB with caspofungin and 
voriconazole, and caspofungin and voriconazole. The two largest studies on the 
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combination of L-AmB and caspofungin comes from the Sloan-Ketering Cancer Centre 
and M.D Anderson Cancer Centre.202,40 In the Sloan-Ketering study202 a combination of 
caspofungin and L-AmB was received by a total of 30 patients with acute or chronic 
leukaemia, (67%) who had pulmonary aspergillosis. A favourable clinical and 
radiographic response was manifested in 60% of the patients to the combination regimen. 
In the M.D Anderson study40 a total of 48 evaluable patients, 23 with proven or probable 
aspergillosis and 25 with possible aspergillosis received a combination of caspofungin 
and L-AMB. The overall favourable response was higher in patients with possible 
infections (42%), but the response rate for patients with proven or probable infections 
was dramatically lower. No significant toxicity was associated in this combination 
regimen in both the above analyses.40, 202 This was supported by findings from smaller 
case series (each < 10 patients) that no worsening toxicity was associated with the 
combination of caspofungin and a polyene.203,204  It was concluded that the dual-therapy 
with caspofungin and L-AmB was safe and well tolerated.205 
 The findings of the side effects reported from this study on patients on a combination of 
L-AmB and caspofungin showed that the patient did not have any major toxicities, 
though the sample size was insufficient, they supported the above findings.  
Voriconazole has a greater potential to alter the pharmacokinetics of co-administered 
drugs. Though several interactions have been reported, numerous others are suspected, as 
mentioned in the official labelling, these remain unpublished leading in some cases to 
contraindications. Thus it appears premature to compare the frequencies of drug-drug 
interactions compared with other azole agents.206 
In the current study one patient who had invasive aspergillosis identified, received a 
combination of caspofungin and voriconazole for a period of four days, however this 
patient was on long term treatment with L-AmB. For invasive aspergillosis the use of 
concomitant therapy with voriconazole and caspofungin has been less frequently 
evaluated.  
In one series, two patients with leukaemia responded favourably to a regimen of 
caspofungin and voriaconazole for pulmonary aspergillosis and one patient received the 
same regimen to treat disseminated infection.207 A recent study has reported a synergistic 
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effect of voriconazole and caspofungin against itraconazole-resistant strains of 
A.fumigatus.208 An animal model study for treating aspegillus infection reported 
caspofungin in combination with voriconazole reduced the kidney burden in 60% of the 
animals.209 
4.14 Antifungal treatment for noeonates 
The findings of this study demonstrated that L-AmB, C-AmB and a combination of L-
AmB and caspofungin were the drugs used for neonates during the study period. There 
are few controlled studies, despite a 45 year history of amphotericin use, that address 
pharmacokinetics and efficacy in newborns, especially in premature infants. In neonates, 
treatment of Candida infection is based largely on extrapolation of data gathered from 
older patients, which has been reported only as uncontrolled, retrospective analyses of 
amphotericin B outcomes in preterm neonates.210 With doses ranging from 0.5 to 1.5 
mg/kg treatment success in this population has been reported.211,212,213 If no response is 
apparent after several days at the lower dose, a usual approach is to initiate therapy at a 
dose of 0.5 mg/kg and escalate to 1.0 mg/kg.210 Reports of immediate reactions to drug 
administration as seen in adults are absent in neonates and correspondingly do not appear 
to limit therapy with this agent.210 
The largest study214 in neonates used L-AmB with doses ranging from 1mg/kg/day to a 
maximum of 5 mg/kg/day to treat 40 preterm and four term neonates with severe fungal 
infections. Of the population 72.7% had the infection eradicated, including all the full 
term and 28 of the preterm infants; however 12 preterm infants died as a result of 
infection. Fungal eradication was demonstrated in 92% of patients in another prospective 
study 215 of L-AmB where 24 premature infants received doses of 2.5 to 7 mg/kg/day. An 
open label multicentre trial216 which included 11 premature infants, nine of whom 
completed therapy at a dose of 5 mg/kg/day showed an efficacy rate of 75% with the only 
toxicity reported was a mild rise in serum creatinine. Final reports from study conducted 
by Weitkamp et al.217 showed the experience of 21 premature infants who received L-
AmB at doses ranging from 1 to 5 mg/kg/day, had 100% eradication of fungal infection 
and recovered clinically. 
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Although randomized controlled trials of comparisons between L-AmB and C-AmB in 
neonates are lacking, the available information suggests that these formulations are safe 
and effective. However, in neonates C-AmB is well tolerated and significantly cost 
effective.210 
4.15 Resolution of fever in patients undergoing antifungal treatment 
During the current study period it was also interesting to note there was a significant 
improvement in the temperature level of the patients from the day antifungal treatment 
was administered to the cessation of antifungal treatment. The most important factors 
limiting the planned intensity of antineoplastic chemotherapy in cancer patients are 
neutropenia, fever and infection, sometimes causing delays in treatment or reduced 
dosages with obvious potential implications for effectiveness. In addition, side effects 
and cost need to be considered.218 Risk of severe infectious complications and fungal 
infections may be increased by intensive neoplastic treatments, such as those used in 
remission induction of acute leukaemia.219 
Guidelines for the use of antimicrobial agents in neutropenic patients with cancer5 
emphasize that, no specific drug or combination of drugs, and no specific period of 
treatment, no specific scheme  can be unequivocally applied to all febrile neutropenic 
patients. Because the definitions of infectious diseases and criteria used to assess the 
response to therapy vary considerably, the results from study to study are often not 
comparable.5 
In one study L-AmB was more efficacious (63%) than C-AmB (32%) for resolution of 
fever (p=0.03).48 Using resolution of fever as an endpoint in a recent study130 showed 
equivalent success rates of voriconazole and L-AmB (82% vs. 85%). Differences in 
overall survival were reported in two studies. 86% with C-AmB vs. 97% with L-AmB 
and 89% with L-AmB vs. 93% with caspofungin.177,197 In one trial, the overall response 
of itraconazole was superior to that of C-AmB.   
Resolution of fever is influenced by many factors other than IFI and is therfore a matter 
of debate. Inclusion of patients with different risk profiles such as duration of persistent 
fever, variable use of antifungal prophylaxis, differences in haemato-oncological 
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conditions, different durations of antifungal therapy and factors such as open design, 
sample sizes make the comparison of the study results difficult. In summary, there was no 
clear cut superiority of one antifungal agent.12 
4.16 Nephrotoxicity  
The findings from the current study showed that 18.6% of patients had a high serum 
creatinine level hence a low creatinine clearance. It should be mentioned that all patients 
who had a lower creatinine clearance were also on other medications which increase 
serum creatinine such as cyclosporine, diphenhydramine and acyclovir. As a majority of 
the patients were on L-AmB the incidence of nephrotoxicity was low compared to C-
AmB as reported from other studies. An insufficient sample size was available for C-
AmB in this study.  
A retrospective review by Wingard et al.221 of C-AmB in the treatment of fungal 
infections in bone-marrow transplant demonstrated that the incidence of nephrotoxicity 
was found to be 29% and in 53% of the patients doubling of the serum creatinine level 
occurred. In a safety and efficacy analysis salvage therapy,222 L-AmB was given to 556 
patients who were intolerant or refractory to C-AmB and 160 of this population had 
developed renal toxicity (serum creatinine>2.5mg/dL). On treatment with L-AmB a 
significant decrease in serum creatinine levels of these patients was noted and also 71% 
of all L-AmB   treated patients had a stable creatinine level. Compared with C-AmB,223 
patients treated first-line with L-AmB177,197,130 showed lower rates of nephrotoxicity. 
Moreover the dosage of L-AmB and the degree of reduced nephrotoxicity are only 
weakly correlated.181,49 
Within the limitations of our retrospective study, having a small sample size from various 
clinical settings, the number of increased serum creatinine levels suggested that use of L-
AmB associated nephrotoxicity was uncommon, as reported by Wingard et al.221 The rate 
of nephrotoxicity may be partially explained by the increased concomitant use of 
cyclosporine observed in this study, this is supported by a report from a study which 
suggested that there was an increased nephrotoxicity when the two drugs were used 
together.224 Accordingly the patients in this study group with an increased serum 
creatinine level received concomitant nephrotoxic drugs. 
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An article by Cannon et al.225 suggested that L-AmB associated nephrotoxicity was not as 
frequent as that reported by Wingard et al.221 A nephrotoxicity rate of 4.3% (2/46) was 
reported by Cannon et al.225 in their observational study whereas, in this study a 
nephrotoxicity rate of 20% (11/59) was reported. 
A randomised controlled trial226 which included 105 patients with haematologic 
malignancies and with fever of unknown origin after receiving chemotherapy. The 
patients were randomly allocated to receive L-AmB 1mg/kg/day or C-AmB at 0.6 
mg/kg/day for empirical antifungal therapy. The results demonstrated that compared with 
C-AmB group, the incidence of renal toxicity was significantly lower in the L-AmB 
group, 32% vs. 8% respectively (p=0.003). Infusion related reactions were similar in both 
groups (77% for c-AmB vs.73% L-AmB). This trial suggested that compared to C-AmB, 
L-AmB at 1 mg/kg/day produced less nephrotoxicity, with a similar frequency of 
infusion related adverse effects. 
4.17 Cost evaluation 
The economic impact of fungal infection is substantial, with an estimated cost per adult 
of USD 48,732 for candidiasis in hospital costs beyond the cost of care for transplant 
recipients in hospital in 1998. Although less frequent, aspergillosis was even more costly 
to treat with an estimated incremental cost of USD 86,635 in transplant recipients in 
1998.227  
The estimated antifungal cost data for the current study showed that for a patient (no: 43) 
(Table 24) of 11 years of age with a body weight of 57.7 kg who received L-AmB for a 
duration of 31 days, the drug treatment cost was AUD 44,394.00 in the pharmacy setting 
prepared by CIVAS and AUD 45,998.00 in the ward setting prepared by nurses. A total 
antifungal treatment cost of AUD 14,320.00 or AUD 14,838.00 for pharmacy and ward 
settings respectively could have been saved if the L-AmB treatment was ceased at 21 
days. The cost of IV antifungal treatment is markedly dependent on the age and weight of 
the patients and the duration of treatment. For example, a patient of low body weight on 
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the same dose per kilogram treatment for long duration and a patient of higher body 
weight on a dose per kilogram for a short course of antifungal treatment could end up in 
similar treatment cost. This also applies to patients on combination treatment as the basic 
decision of the dose and the duration of treatment depends on the high or low risk profile 
of patients. 
The results from a study228 which examined the cost burden of hospitalization of patients 
with aspergillus and candida infections in Australia from 1995-1999 showed that the 
hospitalisation of 4,583 patients with aspergillosis and 57,758 with candidiasis were 
associated with a hospital cost of AUD 563 million. The mean length of stay in hospital 
was 12 days for aspergillosis diagnosis and the hospital cost was AUD 9,334. For 
disseminated, invasive and non-invasive candidiasis, the respective mean lengths of stays 
were 31, 17 and 12 days and the respective hospital costs were AUD 33,274, AUD 
12,954 and AUD 7,694. 
In the USA, for antifungal prophylaxis, an estimated total hospital cost of US $72,706 
was calculated in a study conducted by Wilson et al.227 from the Maryland Hospital 
Discharge Data Set in 1997.  On the other hand the hospital cost of treating proven fungal 
infections was US $119,926 for transplant recipients with candidiasis and US $157,929 
for those with aspergillosis. Adjusted for inflation, in 2006 this yields a hospital cost of 
US $200,087 and US $263,798 respectively.  
Successful antifungal prophylaxis has the potential to lower the overall costs of care 
because it can reduce the incidence of infection. Different regimens may not be equally 
cost effective as the costs of using various types of prophylaxis vary as do their 
effectiveness. However no suggestion can be made that any prophylaxis reduces the 
additional cost of empiric therapy or treatment of breakthrough infections to zero.229 
With regard to antifungal cost, the dosage should be considered. Without question the 
most effective dosage is basic for this decision; however there is no need to exceed the 
optimal dosage. The dose escalation study of Walsh et al.181 showed that with L-AmB 
doses up to 15 mg/kg in patients with fungal infections, for doses above 10 mg/kg Cmax 
and area AUC did not further increase. This unique pharmacokinetics is thought to be 
explained by the fact that uptake of L-AmB by the reticuloendothelial system occurs with 
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accumulation of AmB in tissues. Before a practice standard is established, confirmation 
of such dosage schemes is needed. 
Duration of antibiotic treatment beyond reasonable periods mentioned in the current 
study adds to the treatment cost. For example, for a randomly selected four patients from 
this study who received L-AmB for more than 30 days, the total treatment costs for 
antifungals prepared in the pharmacy and ward settings were AUD 96,482 and AUD 
124,702 respectively. 
When the additional cost over the optimum period of treatment of 21 days was calculated 
the total cost was found to be AUD 51,329 and AUD 68,594 for pharmacy and ward 
setting preparation respectively (Table 24). If AUD 51,329 could have been saved for 
four patients large savings could be expected for all patients who received prolonged 
antifungal treatment. Adherence to decisions made at the pharmacist-microbiologist 
meeting should be implemented when decisions are made at ward level, because cost 
savings on antifungal treatment can be made if a daily ceasing schedule was followed 
rather than only two or three days per week. From the results it could be seen that 12% of 
patients had their antifungal treatment ceased on Mondays which could have probably be 
done on previous Thursdays and the cost for treatment for four days from the day it 
should have been ceased to the actual day it was stopped could be saved. Treatment cost 
of AUD 1,083 for pharmacy setting and AUD 1,206 for the ward setting preparation 
could probably be saved for four days for a patient of four years of age with 16.2 kg body 
weight (patient number 80) who received an extra 3 mg/kg/day of L-AmB for four days 
(Table 28) 
The current study also suggests an important factor that a reasonable saving can be made 
in pharmacy prepared antifungal by CIVAS than a nurse prepared antifungal in the ward 
setting. As the reconstituted vials cannot be retained in a ward setting, for doses where 
residual drug in the ward setting was discarded, increased the total treatment cost 
dependent on the duration of treatment. A particular dosage regimen controls the amount 
of residual drug and therefore the cost differential. Hospitals often depend on nurses for 
preparation of reconstituted drugs and having a CIVAS at the hospital can generate 
savings in the total drug cost. For example for four patients receiving L-AmB, selected 
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randomly from the study, a total of AUD 28,220 could be saved, if L-AmB was prepared 
in CIVAS and a total of AUD 22,732 could be saved in four patients for antifungal 
treatment when a combination was included as a part of the antifungal regimen.  
The cost data used in the current study have included drug, staff and consumables cost. 
The capital and maintenance cost of the CIVAS unit was not included. This would be 
amortised over numerous preparations.  Similarly the cost of the area used by the nursing 
staff was not included. 
Other costs such as diagnostic procedures, laboratory testing, cost of treating side effects 
of the drug, and monitoring for drug side-effects were not considered. The determined 
cost data relates to a supply cost rather than a total cost. Some of the other hospital costs 
are difficult to apportion to the cost per infusion. 
Results with current antifungal therapies in cancer patients with fungal infections have 
prompted exploration of other methods of improving survival rates. Failure of antifungal 
therapy is not solely a function of the efficacy of a given drug: the ultimate treatment 
outcome is influenced by factors such as underlying disease state, the site of fungal 
infection, multiple organ or organ failure, drug pharmacokinetics and patient 
compliance.230 By the time invasive fungal infections become apparent, many of these 
factors are beyond the scope of medical intervention and therefore the focus has shifted to 
earlier interventional strategies.231 
A thorough study of the epidemiology of fungal infections in cancer patients and criteria 
such as safety, efficacy, cost, consequence of doing so, potential for development of 
resistant strains of fungi and prevalence of fungal infections in a given population should 
be considered before instituting prophylaxis in all patients.232 Development of new pre-
emptive strategies aimed at distinguishing patients who need antifungal prophylaxis or 
empirical treatment should be investigated. The new antifungal agents may provide 
exciting options for combination antifungal therapy being active against some fungi 
resistant to L-AmB and may have a role in the management of fever and neutropenia.233 
Reduced nephrotoxicity with L-AMB and other antifungal agents are important 
improvements. However antifungal efficacy remains the most important consideration in 
choosing the most appropriate agent in the face of fungal infections. If cost were of no 
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consequence L-AmB would probably still be the accepted standard of care for empirical 
therapy. The dose of 3 mg/kg/day although commonly accepted is based on clinical usage 
rather than a strong evidence base in children.19 However, when toxicity and efficacy are 
taken into consideration L-AmB may not be as expensive as it appears. 
In cases of mycoses that are refractory to treatment or for which no established treatment 
exists, it appears that combination of antifungal drugs is a logical step.10 However, since 
few clinical data are available combinations are used on an empirical basis in most cases. 
However, prospective clinical trials to evaluate various combinations of antifungal are  
supported by some data obtained from  in-vitro animal model and clinical studies.234 
 The current study was a treatment audit. The value of carrying out such studies includes 
an insight into how the hospital guidelines are followed. Such a study provides important 
information and demonstrates an increased understanding of the most effective means 
antifungal treatment, adverse effects. Audits help hospitals identify barriers to guideline 
adherence. In this case, overall IV antifungal treatment followed acceptable guidelines 
and no specific intervention could be proposed from the findings. Lengthy treatments 
however require regular reviews. Some savings could be made by ceasing the drug on 
any day rather than mainly at two ward rounds each week. 
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5 CONCLUSION 
The cost of patient care will increase with the inappropriate use of antifungal agents and 
may diminish its quality. Moreover, with the ever increasing budgetary constraints and 
arrival of competitive market in health care, the direct cost of prescribing inappropriate 
antifungal therapy may mean that any further opportunity for employing more useful 
alternatives may be fortified.235 This could be prevented by improving prescribing 
practices. However, significant questions remain, including the efficacy of the new 
antifungal agents against less common fungi and the management of breakthrough 
infections and treatment failures.233 
At present understanding of newer antifungal agents in children is limited. In future 
children should be included in the studies of new antifungal drugs and combination 
therapy and stratify the results by age, given the potential differences in 
pharmacokinetics, pharmacodynamics, efficacy and safety.2  Further studies are needed 
to judge the use of antifungals to allow empirical antifungal therapy or antifungal 
prophylaxis. 
The understanding of the most effective means of treating disseminated fungal disease in 
the immunocompromised cancer patients could be greatly increased by the information 
gained from rigorously controlled and statistically valid studies.231 In patients with 
difficult to treat infections or infections due to suspected resistant strains, the use of 
combination therapy remains an important empirical strategy and the decision of what 
treatment to use in each cases should be individualised.236 Finally, further evolution of 
treatment and prevention strategies together with surgical intervention and timely 
diagnosis are urgently required.115 
In summary, the data from this study indicated a satisfactory concordance of IV 
antifungal treatment with guidelines. However, the remaining requirements for 
appropriate use required additional education. It was concluded from this study that L-
AmB still remains the antifungal agent of choice for the majority of cases which were 
reported to be acute myeloid leukaemia. The use of newer antifungal agents 
(voriconazole, caspofungin and posaconazole) should be taken into consideration as very 
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few patients in this study population were prescribed any of the newer antifungal drugs. 
This study also showed that combination antifungal therapy were prescribed to five out of 
59 patients included in this study and this limited evidence supports a need for further 
studies of  combination therapy and the combination choice and individual dosages.  
Majority of the patients received 3 and 5 mg/kg/day of L-AmB which is the 
recommended paediatric dosage in the Australian Therapeutic Guidelines. It was also 
noted that the mean temperature of the patients undergoing antifungal treatment was 
reduced by the end of the therapy. Nephrotoxicity was reported only in 18% of the paient. 
The total drug cost is reduced if the drug was prepared in the Pharmacy CIVAS. The days 
on which IV treatment is ceased should be reviewed to identify if cost savings can be 
achieved.  
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